UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
5696,Clearstream,Twitter API,Twitter,@Lawditeur J'ai le CD-ROM de Clearstream.#Kinanveu ?,nan,@Lawditeur J'ai le CD-ROM de Clearstream.#Kinanveu ?,neutral,0.07,0.86,0.07,neutral,0.07,0.86,0.07,True,English,"['Lawditeur', 'CD-ROM', 'Clearstream', 'Lawditeur', 'CD-ROM', 'Clearstream']",2022-05-29,2022-06-05,Unknown
5722,Clearstream,Twitter API,Twitter,Russia's National Settlement Depository says Clearstream is blocking its account -Ifx https://t.co/uS5OBDxM9a,nan,Russia's National Settlement Depository says Clearstream is blocking its account -Ifx https://t.co/uS5OBDxM9a,negative,0.02,0.35,0.63,negative,0.02,0.35,0.63,True,English,"['National Settlement Depository', 'Russia', 'Clearstream', 'account', 'uS5OBDxM9a', 'National Settlement Depository', 'Russia', 'Clearstream', 'account', 'uS5OBDxM9a']",2022-05-30,2022-06-05,Unknown
5731,Deutsche Boerse,Twitter API,Twitter,Illuminate Financial secures commitments from Jefferies  JPMorgan  S&amp;amp;P Global and Deutsche B&amp;#246;rse https://t.co/yLcyRzZDJ6,nan,Illuminate Financial secures commitments from Jefferies  JPMorgan  S&amp;amp;P Global and Deutsche B&amp;#246;rse https://t.co/yLcyRzZDJ6,neutral,0.01,0.97,0.01,neutral,0.01,0.97,0.01,True,English,"['Illuminate Financial', 'P Global', 'commitments', 'Jefferies', 'JPMorgan', 'yLcyRzZDJ6', 'Illuminate Financial', 'P Global', 'commitments', 'Jefferies', 'JPMorgan', 'yLcyRzZDJ6']",2022-05-29,2022-06-05,Unknown
5777,Euroclear,Twitter API,Twitter,Neobank Kroo lands ¬£26m in Series B funding round #AAA Websites Euroclear Fintech https://t.co/QBDIIfPXCd #regtech,nan,Neobank Kroo lands ¬£26m in Series B funding round #AAA Websites Euroclear Fintech https://t.co/QBDIIfPXCd #regtech,neutral,0.02,0.93,0.04,neutral,0.02,0.93,0.04,True,English,"['Series B funding round', 'Neobank Kroo', 'Fintech', 'co', 'QBDIIfPXCd', 'regtech', 'Series B funding round', 'Neobank Kroo', 'Fintech', 'co', 'QBDIIfPXCd', 'regtech']",2022-06-01,2022-06-05,Unknown
5778,Euroclear,Twitter API,Twitter,Stephen Lancaster appointed CEO at GB Bank #AAA Websites Euroclear Fintech https://t.co/WIF6KvyU1J #regtech,nan,Stephen Lancaster appointed CEO at GB Bank #AAA Websites Euroclear Fintech https://t.co/WIF6KvyU1J #regtech,neutral,0.01,0.99,0.01,neutral,0.01,0.99,0.01,True,English,"['Stephen Lancaster', 'GB Bank', 'CEO', 'Fintech', 'WIF6KvyU1J', 'regtech', 'Stephen Lancaster', 'GB Bank', 'CEO', 'Fintech', 'WIF6KvyU1J', 'regtech']",2022-06-01,2022-06-05,Unknown
5779,Euroclear,Twitter API,Twitter,Litigation leaves CFPB‚Äôs payday rule in limbo¬† #AAA Websites Euroclear Fintech https://t.co/rvd6ZAi1xg #regtech,nan,Litigation leaves CFPB‚Äôs payday rule in limbo¬† #AAA Websites Euroclear Fintech https://t.co/rvd6ZAi1xg #regtech,neutral,0.03,0.57,0.4,neutral,0.03,0.57,0.4,True,English,"['payday rule', 'Litigation', 'CFPB', 'limbo', 'Fintech', 'co', 'rvd6ZAi1xg', 'regtech', 'payday rule', 'Litigation', 'CFPB', 'limbo', 'Fintech', 'co', 'rvd6ZAi1xg', 'regtech']",2022-06-01,2022-06-05,Unknown
5780,Euroclear,Twitter API,Twitter,PNC Financial announces a new head of retail banking #AAA Websites Euroclear Fintech https://t.co/6Hr3mxd0m6 #regtech,nan,PNC Financial announces a new head of retail banking #AAA Websites Euroclear Fintech https://t.co/6Hr3mxd0m6 #regtech,neutral,0.01,0.98,0.01,neutral,0.01,0.98,0.01,True,English,"['PNC Financial', 'new head', 'retail banking', 'Fintech', 'regtech', 'PNC Financial', 'new head', 'retail banking', 'Fintech', 'regtech']",2022-05-31,2022-06-05,Unknown
5781,Euroclear,Twitter API,Twitter,New EMVCo protocol aims to simplify contactless payments #AAA Websites Euroclear Fintech https://t.co/lJeBUmaN0v #regtech,nan,New EMVCo protocol aims to simplify contactless payments #AAA Websites Euroclear Fintech https://t.co/lJeBUmaN0v #regtech,neutral,0.01,0.98,0.01,neutral,0.01,0.98,0.01,True,English,"['New EMVCo protocol', 'contactless payments', 'Fintech', 'lJeBUmaN0v', 'regtech', 'New EMVCo protocol', 'contactless payments', 'Fintech', 'lJeBUmaN0v', 'regtech']",2022-05-31,2022-06-05,Unknown
5782,Euroclear,Twitter API,Twitter,ADCB Egypt partners Temenos to deliver digital payments #AAA Websites Euroclear Fintech https://t.co/d4EyyBz4ry #regtech,nan,ADCB Egypt partners Temenos to deliver digital payments #AAA Websites Euroclear Fintech https://t.co/d4EyyBz4ry #regtech,neutral,0.01,0.98,0.01,neutral,0.01,0.98,0.01,True,English,"['ADCB Egypt partners', 'digital payments', 'Temenos', 'Fintech', 'd4EyyBz4ry', 'regtech', 'ADCB Egypt partners', 'digital payments', 'Temenos', 'Fintech', 'd4EyyBz4ry', 'regtech']",2022-05-31,2022-06-05,Unknown
5792,Clearstream,Twitter API,Twitter,@CSCarbon and @SusthubTraining were delighted to take part in the #ESGSummit22 yesterday. Thanks to the Clearstream‚Ä¶ https://t.co/oFjixPoO9l,nan,@CSCarbon and @SusthubTraining were delighted to take part in the #ESGSummit22 yesterday. Thanks to the Clearstream‚Ä¶ https://t.co/oFjixPoO9l,positive,0.98,0.01,0.0,positive,0.98,0.01,0.0,True,English,"['part', 'Clearstream', 'oFjixPoO9l', 'part', 'Clearstream', 'oFjixPoO9l']",2022-06-01,2022-06-05,Unknown
5793,Clearstream,Twitter API,Twitter,@CSCarbon were delighted to take part in the #ESGSummit22 yesterday. Thanks to the Clearstream Solutions team  Irel‚Ä¶ https://t.co/3XPKH0ATTc,nan,@CSCarbon were delighted to take part in the #ESGSummit22 yesterday. Thanks to the Clearstream Solutions team  Irel‚Ä¶ https://t.co/3XPKH0ATTc,positive,0.98,0.02,0.0,positive,0.98,0.02,0.0,True,English,"['Clearstream Solutions team', 'part', 'Irel', 'XPKH0ATTc', 'Clearstream Solutions team', 'part', 'Irel', 'XPKH0ATTc']",2022-06-01,2022-06-05,Unknown
5794,Clearstream,Twitter API,Twitter,We are delighted to have the Clearstream Solutions team here at #ESGSummit22. @CSCarbon is Ireland‚Äôs leading inde‚Ä¶ https://t.co/HAjdm6zrG2,nan,We are delighted to have the Clearstream Solutions team here at #ESGSummit22. @CSCarbon is Ireland‚Äôs leading inde‚Ä¶ https://t.co/HAjdm6zrG2,positive,0.96,0.03,0.0,positive,0.96,0.03,0.0,True,English,"['Clearstream Solutions team', 'Ireland', 'HAjdm6zrG2', 'Clearstream Solutions team', 'Ireland', 'HAjdm6zrG2']",2022-05-31,2022-06-05,Unknown
5797,Deutsche Boerse,Twitter API,Twitter,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/0UiNeyv5my,nan,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/0UiNeyv5my,positive,0.76,0.23,0.01,positive,0.76,0.23,0.01,True,English,"['inspiring session', 'Amsterdam', 'innovation', '0UiNeyv5my', 'inspiring session', 'Amsterdam', 'innovation', '0UiNeyv5my']",2022-06-01,2022-06-05,Unknown
5798,Deutsche Boerse,Twitter API,Twitter,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/aM564Q2hmZ,nan,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/aM564Q2hmZ,positive,0.76,0.23,0.01,positive,0.76,0.23,0.01,True,English,"['inspiring session', 'Amsterdam', 'innovation', 'aM564Q2hmZ', 'inspiring session', 'Amsterdam', 'innovation', 'aM564Q2hmZ']",2022-06-01,2022-06-05,Unknown
5799,Deutsche Boerse,Twitter API,Twitter,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/dMsAb42CrJ,nan,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/dMsAb42CrJ,positive,0.76,0.23,0.01,positive,0.76,0.23,0.01,True,English,"['inspiring session', 'Amsterdam', 'innovation', 'dMsAb42CrJ', 'inspiring session', 'Amsterdam', 'innovation', 'dMsAb42CrJ']",2022-06-01,2022-06-05,Unknown
5800,Deutsche Boerse,Twitter API,Twitter,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/EQvQqhsFuT,nan,Join us in Amsterdam for an inspiring session with @Lars Bolanca of @Deutsche Boerse on how innovation has been fue‚Ä¶ https://t.co/EQvQqhsFuT,positive,0.76,0.23,0.01,positive,0.76,0.23,0.01,True,English,"['inspiring session', 'Amsterdam', 'innovation', 'EQvQqhsFuT', 'inspiring session', 'Amsterdam', 'innovation', 'EQvQqhsFuT']",2022-06-01,2022-06-05,Unknown
5801,Deutsche Boerse,Twitter API,Twitter,Deana Lawson wins the Deutsche B√∂rse Photography Foundation Prize 2022 - The Eye of Photography https://t.co/YaGc9i2BiN,nan,Deana Lawson wins the Deutsche B√∂rse Photography Foundation Prize 2022 - The Eye of Photography https://t.co/YaGc9i2BiN,neutral,0.02,0.97,0.01,neutral,0.02,0.97,0.01,True,English,"['Deutsche B√∂rse Photography Foundation Prize', 'Deana Lawson', 'The Eye', 'YaGc9i2BiN', 'Deutsche B√∂rse Photography Foundation Prize', 'Deana Lawson', 'The Eye', 'YaGc9i2BiN']",2022-06-01,2022-06-05,Unknown
5901,Euroclear,Twitter API,Twitter,Best Places to Work in Fintech 2022 #AAA Websites Euroclear Fintech https://t.co/7aTTfe5ojI #regtech,nan,Best Places to Work in Fintech 2022 #AAA Websites Euroclear Fintech https://t.co/7aTTfe5ojI #regtech,neutral,0.16,0.83,0.01,neutral,0.16,0.83,0.01,True,English,"['Best Places', 'Fintech 2022', 'aTTfe5ojI', 'regtech', 'Best Places', 'Fintech 2022', 'aTTfe5ojI', 'regtech']",2022-06-01,2022-06-05,Unknown
5904,Clearstream,Twitter API,Twitter,‚ú®@bestbuy Sale Alert! ‚ú®$20 off the ClearStream 4MAX Complete until 6/11.Shop now: https://t.co/UITbHNXVYm‚Ä¶ https://t.co/Rf80kuM9HL,nan,‚ú®@bestbuy Sale Alert! ‚ú®$20 off the ClearStream 4MAX Complete until 6/11.Shop now: https://t.co/UITbHNXVYm‚Ä¶ https://t.co/Rf80kuM9HL,positive,0.98,0.02,0.0,positive,0.98,0.02,0.0,True,English,"['bestbuy Sale Alert', 'ClearStream 4MAX', 'Shop', 'UITbHNXVYm', 'Rf80kuM9HL', 'bestbuy Sale Alert', 'ClearStream 4MAX', 'Shop', 'UITbHNXVYm', 'Rf80kuM9HL']",2022-06-02,2022-06-05,Unknown
5905,Clearstream,Twitter API,Twitter,Winning this one today. Clearstream maintenance &amp; sample Beauty really is in the eye of the wastewater service‚Ä¶ https://t.co/lQXo87fdT7,nan,Winning this one today. Clearstream maintenance &amp; sample Beauty really is in the eye of the wastewater service‚Ä¶ https://t.co/lQXo87fdT7,positive,0.95,0.03,0.02,positive,0.95,0.03,0.02,True,English,"['Clearstream maintenance', 'wastewater service', 'sample', 'Beauty', 'eye', 'lQXo87fdT7', 'Clearstream maintenance', 'wastewater service', 'sample', 'Beauty', 'eye', 'lQXo87fdT7']",2022-06-02,2022-06-05,Unknown
5908,Deutsche Boerse,Twitter API,Twitter,üìà Deutsche B√∂rse‚Äôs Cash Markets Rise 3% MoM to ‚Ç¨161.6bn in May üìâby @CraftyFinThe cash markets of Deutsche B√∂rse ‚Ä¶ https://t.co/yYCDbpcSjF,nan,üìà Deutsche B√∂rse‚Äôs Cash Markets Rise 3% MoM to ‚Ç¨161.6bn in May üìâby @CraftyFinThe cash markets of Deutsche B√∂rse ‚Ä¶ https://t.co/yYCDbpcSjF,neutral,0.04,0.93,0.03,neutral,0.04,0.93,0.03,True,English,"['Deutsche B√∂rse', 'Cash Markets', 'May', 'yYCDbpcSjF', 'Deutsche B√∂rse', 'Cash Markets', 'May', 'yYCDbpcSjF']",2022-06-02,2022-06-05,Unknown
5947,Euroclear,Twitter API,Twitter,@RobinWigg I wouldn't bet on BNY  Clearstream or Euroclear to solve it. You need an outsider to cut that Gordian knot.,nan,@RobinWigg I wouldn't bet on BNY  Clearstream or Euroclear to solve it. You need an outsider to cut that Gordian knot.,negative,0.02,0.42,0.56,negative,0.02,0.42,0.56,True,English,"['Gordian knot', 'BNY', 'Clearstream', 'Euroclear', 'outsider', 'Gordian knot', 'BNY', 'Clearstream', 'Euroclear', 'outsider']",2022-06-03,2022-06-05,Unknown
5948,Euroclear,Twitter API,Twitter,Bank CEO compensation soared last year alongside surging stock prices #AAA Websites Euroclear Fintech https://t.co/WyLitw1Nqb #regtech,nan,Bank CEO compensation soared last year alongside surging stock prices #AAA Websites Euroclear Fintech https://t.co/WyLitw1Nqb #regtech,neutral,0.03,0.93,0.05,neutral,0.03,0.93,0.05,True,English,"['Bank CEO compensation', 'surging stock prices', 'Fintech', 'WyLitw1Nqb', 'regtech', 'Bank CEO compensation', 'surging stock prices', 'Fintech', 'WyLitw1Nqb', 'regtech']",2022-06-03,2022-06-05,Unknown
5957,Clearstream,Twitter API,Twitter,@RobinWigg I wouldn't bet on BNY  Clearstream or Euroclear to solve it. You need an outsider to cut that Gordian knot.,nan,@RobinWigg I wouldn't bet on BNY  Clearstream or Euroclear to solve it. You need an outsider to cut that Gordian knot.,negative,0.02,0.42,0.56,negative,0.02,0.42,0.56,True,English,"['Gordian knot', 'BNY', 'Clearstream', 'Euroclear', 'outsider', 'Gordian knot', 'BNY', 'Clearstream', 'Euroclear', 'outsider']",2022-06-03,2022-06-05,Unknown
5958,Clearstream,Twitter API,Twitter,Listening recommendation: together with @ClimateBonds  we joined the latest episode of @Clearstream‚Äôs GFF #podcast‚Ä¶ https://t.co/pXfNj6qSwI,nan,Listening recommendation: together with @ClimateBonds  we joined the latest episode of @Clearstream‚Äôs GFF #podcast‚Ä¶ https://t.co/pXfNj6qSwI,positive,0.62,0.35,0.03,positive,0.62,0.35,0.03,True,English,"['Listening recommendation', 'latest episode', 'GFF #podcast', 'pXfNj6qSwI', 'Listening recommendation', 'latest episode', 'GFF #podcast', 'pXfNj6qSwI']",2022-06-03,2022-06-05,Unknown
5959,Clearstream,Twitter API,Twitter,üëç on @YouTube: Streaming Live TV And Cutting The Cord! | ClearStream TV üì∫ https://t.co/z51oRtL5II,nan,üëç on @YouTube: Streaming Live TV And Cutting The Cord! | ClearStream TV üì∫ https://t.co/z51oRtL5II,neutral,0.08,0.87,0.05,neutral,0.08,0.87,0.05,True,English,"['Live TV', 'The Cord', 'ClearStream TV', 'z51oRtL5II', 'Live TV', 'The Cord', 'ClearStream TV', 'z51oRtL5II']",2022-06-03,2022-06-05,Unknown
5986,EuroNext,Twitter API,Twitter,Hallo from Amsterdam üëãüå∑We're meeting in person today at the #EUeic's Investor Day with @euronext!2Ô∏è‚É£0Ô∏è‚É£ EIC ben‚Ä¶ https://t.co/WBrijmkTg1,nan,Hallo from Amsterdam üëãüå∑We're meeting in person today at the #EUeic's Investor Day with @euronext!2Ô∏è‚É£0Ô∏è‚É£ EIC ben‚Ä¶ https://t.co/WBrijmkTg1,positive,0.73,0.25,0.03,positive,0.73,0.25,0.03,True,English,"['Investor Day', 'Hallo', 'Amsterdam', 'person', 'EIC', 'WBrijmkTg1', 'Investor Day', 'Hallo', 'Amsterdam', 'person', 'EIC', 'WBrijmkTg1']",2022-06-03,2022-06-05,Unknown
5987,EuroNext,Twitter API,Twitter,Terracom participated on the EIC &amp; Euronext Investor Day in Amsterdam on the 3rd of June 2022. Mr. Stelios Gkouskos‚Ä¶ https://t.co/3t6pwqk1Mp,nan,Terracom participated on the EIC &amp; Euronext Investor Day in Amsterdam on the 3rd of June 2022. Mr. Stelios Gkouskos‚Ä¶ https://t.co/3t6pwqk1Mp,neutral,0.03,0.94,0.02,neutral,0.03,0.94,0.02,True,English,"['Euronext Investor Day', 'Mr. Stelios Gkouskos', 'Terracom', 'EIC', 'Amsterdam', '3rd', 'June', 't6pwqk1Mp', 'Euronext Investor Day', 'Mr. Stelios Gkouskos', 'Terracom', 'EIC', 'Amsterdam', '3rd', 'June', 't6pwqk1Mp']",2022-06-03,2022-06-05,Unknown
5992,Euroclear,Twitter API,Twitter,Jobinar: Euroclear ‚Äì Operations &amp; Client Service Professionalshttps://t.co/9ttxWZkmmR https://t.co/pdA839ouQM,nan,Jobinar: Euroclear ‚Äì Operations &amp; Client Service Professionalshttps://t.co/9ttxWZkmmR https://t.co/pdA839ouQM,neutral,0.01,0.99,0.01,neutral,0.01,0.99,0.01,True,English,"['Client Service Professionals', 'Jobinar', 'Euroclear', 'Operations', '9ttxWZkmmR', 'pdA839ouQM', 'Client Service Professionals', 'Jobinar', 'Euroclear', 'Operations', '9ttxWZkmmR', 'pdA839ouQM']",2022-06-04,2022-06-05,Unknown
5994,Clearstream,Google API,https://weirdnewsera.com/is-metv-on-pluto-tv/,Is Metv On Pluto TV - Weird News Era,1 day ago,Pluto TV is a popular free streaming service that provides users with access to hundreds of virtual channels with an experience that is similar to that of cable TV. You won‚Äôt have to pay a dime to watch movies  television shows  or even live programming when you stream them online. However  given that there are over 250 different channels available on Pluto TV  the question becomes: which ones should you begin with?Thats a fantastic question. The reality is that there is such a wide variety of channels and categories available to watch on Pluto TV that it will ultimately come down to your personal preferences to determine which ones you will continue to watch. Nevertheless  we believe that we can point you in the correct path by providing you with our recommendations for the top Pluto TV channels.How Can I Watch Metv Without CableYou can pause  rewind  and watch all of your favorite network shows using the free ClearStream TV companion app and any HDTV antenna with no subscription or monthly fees from *ABC  CBS  NBC  Fox  PBS  myTV  ION  MeTV  The CW  and Univision  along with expanded programming  using the FREE ClearStream TV companion app and an HDTV antenna. In addition  you can watch expanded programming using the FREE ClearStream TV companion app and an HDTV antenna.Pluto TV Is Adding Support For Live Local ChannelsOn several popular streaming media players  including Rokus and Fire TVs  Pluto TV is one of the most popular free streaming applications available. Many people who have dropped their cable or satellite television subscriptions appreciate this app since it integrates a diverse selection of material into a single user experience.Now Pluto TV is doing tests to see if it is possible to include the local channels that you receive from your antenna directly into the Pluto TV interface. If you have a Roku TV and an antenna attached to it  you will be able to access your local channels directly within the Pluto TV user interface. This is only possible if you own a Roku TV.Because we were unable to locate a significant amount of information regarding this newly added feature  we contacted Ilya Pozin  an employee at Pluto TV. This is what we have picked up.During this period of beta testing  Pluto TV will only display a maximum of 15 channels within the Pluto TV guide. It was said that this was just for the preliminary test  and that Pluto will continue to enhance support as it receives input from the community.Because Pluto obtains its data from the Roku TV  you need to ensure that your antenna is properly connected to the Roku TV. This is simply a preliminary test for the beta version. It has stated that  based on how the community responds to this test  it may explore extending support to more devices and increasing the support for live TV. At the moment  it does not support other devices such as Android TV.What Is Pluto TVThe term ‚Äúover-the-top‚Äù refers to the fact that Pluto TV is a service that is delivered through the internet as opposed to being broadcast on dedicated lines or over the air. A video-on-demand service that is supported by advertisements is also included. This places it in the same category as other free streaming services such as Crackle  Tubi  and Sling Free.You can watch Pluto TV by streaming it on the website  or you can download the app to use it on any of the numerous devices that are compatible with the service.The Andy Griffith ShowOther stations on Pluto TV are devoted to continuously broadcasting classic comedies including Happy Days  Threes Company  and Family Ties. These channels are available around the clock. For our money  we believe that the sitcom station that is dedicated to broadcasting episodes of The Andy Griffith Show is the best of these several sitcom channels. In contrast to the majority of sitcoms  which take place in large cities  this one is situated in the fictional town of Mayberry  North Carolina. There  the local sheriff  Andy Taylor  does not need to carry a pistol in order to maintain order. This program still manages to be amusing  yet it still has the ability to tug at your emotions on occasion.How To Watch Metv On The RokuHowever  some MeTV-affiliated stations carry the network as a primary affiliation on their main channel  and a small number of stations air select programs from the network alongside their regular general entertainment schedules. MeTV is carried on digital subchannels of affiliated television stations in most markets. However  some MeTV-affiliated stations carry the network as a primary affiliation on their main channel. In addition  the network can be received throughout the United States via the free-to-air C band satellite through SES-1 in the DVB-S format; in certain areas  it can also be received on AT&T U-verse channels 136 and 1136. MeTV‚Äôs business operations are managed from the Weigel Broadcasting corporate headquarters  which are located in Chicago  Illinois  on North Halsted Street.Tablo is a next-generation digital video recorder (DVR) that can record free  local HDTV broadcast programs like news and sports inside the United States and Canada by plugging into a digital TV antenna. Tablo does not include an HDMI connection  in contrast to more conventional DVRs that are only linked to a single television. Tablo can connect to your home network by WiFi or Ethernet  allowing it to stream video to any connected device in your home or anywhere else in the world where you have internet access.The Over-The-Air (OTA) DVR service offered by Tablo provides live  local HDTV broadcast programs that are unavailable via Over-The-Top (OTT) online content providers such as Amazon Prime  Hulu  and Netflix. You won‚Äôt have to wait until the next day to watch your favorite network shows live  and you won‚Äôt have to pay the expensive cable fee either. Catch up on the local news and sports  and watch your favorite shows live.,negative,0.02,0.07,0.91,mixed,0.76,0.1,0.14,True,English,"['Weird News Era', 'Pluto TV', 'several popular streaming media players', 'free ClearStream TV companion app', 'free, local HDTV broadcast programs', 'popular free streaming applications', 'regular general entertainment schedules', 'Weigel Broadcasting corporate headquarters', 'other free streaming services', 'popular free streaming service', 'next-generation digital video recorder', 'AT&T U-verse channels', 'The Andy Griffith Show', 'air C band satellite', 'Pluto TV user interface', 'top Pluto TV channels', 'satellite television subscriptions', 'several sitcom channels', 'single user experience', 'North Halsted Street', 'Pluto TV interface', 'Pluto TV guide', 'Live Local Channels', 'favorite network shows', 'Andy Taylor', 'digital subchannels', 'live TV', 'television shows', 'local sheriff', 'The CW', 'Android TV', 'sitcom station', 'North Carolina', 'Other stations', 'Roku TV', 'live programming', 'other devices', 'virtual channels', '250 different channels', 'HDTV antenna', 'television stations', 'wide variety', 'personal preferences', 'correct path', 'monthly fees', 'expanded programming', 'Fire TVs', 'Many people', 'diverse selection', 'significant amount', 'Ilya Pozin', 'beta testing', 'beta version', 'dedicated lines', 'demand service', 'same category', 'classic comedies', 'Happy Days', 'Threes Company', 'Family Ties', 'large cities', 'fictional town', 'primary affiliation', 'main channel', 'small number', 'most markets', 'United States', 'DVB-S format', 'business operations', 'cable TV', 'MeTV-affiliated stations', 'preliminary test', 'numerous devices', 'fantastic question', '15 channels', 'users', 'access', 'hundreds', 'dime', 'movies', 'reality', 'categories', 'recommendations', 'CBS', 'NBC', 'Fox', 'PBS', 'myTV', 'Univision', 'addition', 'Support', 'Rokus', 'material', 'tests', 'information', 'feature', 'employee', 'period', 'maximum', 'input', 'community', 'data', 'moment', 'term', 'fact', 'internet', 'advertisements', 'Crackle', 'Tubi', 'Sling', 'website', 'clock', 'money', 'episodes', 'contrast', 'majority', 'sitcoms', 'place', 'Mayberry', 'pistol', 'ability', 'emotions', 'occasion', 'SES-1', 'areas', 'Chicago', 'Illinois', 'Tablo', 'DVR', 'news']",2022-06-05,2022-06-05,weirdnewsera.com
5995,Clearstream,Google API,https://nuhey.news/2022/06/04/global-bio-neutral-polishing-enzyme-market-report-segmentation-by-types-application-regions-and-by-companies/,Global Bio-neutral Polishing Enzyme Market Report: Segmentation by Types  Application  Regions  and by Companies ‚Äì Nuhey News,1 day ago,Due to the COVID-19 pandemic  the global Bio-neutral Polishing Enzyme market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis  Quick Exchange Type accounting for % of the Bio-neutral Polishing Enzyme global market in 2021  is projected to value US$ million by 2028  growing at a revised % CAGR from 2022 to 2028. While Biological Industry segment is altered to an % CAGR throughout this forecast period.North America Bio-neutral Polishing Enzyme market is estimated at US$ million in 2021  while Europe is forecast to reach US$ million by 2028. The proportion of the North America is % in 2021  while Europe percentage is %  and it is predicted that Europe share will reach % in 2028  trailing a CAGR of % through the analysis period 2022-2028. As for the Asia  the notable markets are Japan and South Korea  CAGR is % and % respectively for the next 6-year period.The research report has incorporated the analysis of different factors that augment the market‚Äôs growth. It constitutes trends  restraints  and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and about each type from 2017 to 2028. This section mentions the volume of production by region from 2017 to 2028. Pricing analysis is included in the report according to each type from the year 2017 to 2028  manufacturer from 2017 to 2022  region from 2017 to 2022  and global price from 2017 to 2028.A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally  insights into market expert‚Äôs opinions have been taken to understand the market better.Request for a free sample or purchase this report at: https://www.themarketreports.com/report/global-bio-neutral-polishing-enzyme-market-research-reportThe research report includes specific segments by region (country)  by manufacturers  by Type and by Application. Each type provides information about the production during the forecast period of 2016 to 2027. by Application segment also provides consumption during the forecast period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Segment by TypeQuick Exchange TypeOverall Exchange TypeFixed Guide Wire TypePerfusion TypeSegment by ApplicationBiological IndustryChemical IndustryBy CompanyAachen ResonanceAccura MedizintechnikAcrostakCordisAlvimedicaDegania SiliconeAngioScoreArthesysBaltonClearstream TechnologiesBiotronikBrosMed MedicalProduction by RegionNorth AmericaEuropeChinaConsumption by RegionNorth America (United States  Canada)Europe (Germany  France  U.K.  Italy  Russia)Asia-Pacific (China  Japan  South Korea  India  Australia  China Taiwan  Indonesia  Thailand  Malaysia)Latin America (Mexico  Brazil  Argentina)Middle East & Africa (Turkey  Saudi Arabia  UAE)Contact Details:Mr. Shirish GuptaSales ManagerThe Market Reports | Industry and Market Reports at its BestCall: +1-631-407-1315 / +91-750-729-1479Email: sales@themarketreports.com,neutral,0.01,0.99,0.01,mixed,0.7,0.16,0.14,True,English,"['Global Bio-neutral Polishing Enzyme Market Report', 'Nuhey News', 'Segmentation', 'Types', 'Application', 'Regions', 'Companies', 'Mr. Shirish Gupta Sales Manager', 'global Bio-neutral Polishing Enzyme market size', 'Bio-neutral Polishing Enzyme global market', 'Fixed Guide Wire Type', 'Biological Industry Chemical Industry', 'Biological Industry segment', 'next 6-year period', 'Quick Exchange Type', 'Overall Exchange Type', 'The Market Reports', 'BrosMed Medical Production', 'Perfusion Type Segment', 'global price', 'growing market', 'market expert', 'forecast period', 'market growth', 'COVID-19 pandemic', 'economic change', 'health crisis', 'North America', 'notable markets', 'South Korea', 'negative manner', 'historic milestones', 'thorough evaluation', 'strategic planning', 'different bends', 'lucrative opportunities', 'free sample', 'Aachen Resonance', 'Accura Medizintechnik', 'Acrostak Cordis', 'Degania Silicone', 'Clearstream Technologies', 'United States', 'U.K.', 'Latin America', 'Middle East', 'Saudi Arabia', 'Contact Details', 'different factors', 'different segments', 'specific segments', 'analysis period', 'Application segment', 'detailed information', 'current trends', 'Pricing analysis', 'Europe percentage', 'Europe share', 'research report', 'China Taiwan', 'CAGR', 'proportion', 'Asia', 'Japan', 'restraints', 'drivers', 'positive', 'section', 'scope', 'applications', 'future', 'volume', 'region', 'manufacturer', 'restrains', 'contrast', 'room', 'hold', 'insights', 'opinions', 'Request', 'themarketreports', 'global-bio-neutral-polishing-enzyme-market-research-report', 'country', 'consumption', 'importance', 'Company', 'Alvimedica', 'AngioScore', 'Arthesys', 'Balton', 'Biotronik', 'Canada', 'Germany', 'France', 'Italy', 'Russia', 'India', 'Australia', 'Indonesia', 'Thailand', 'Malaysia', 'Mexico', 'Brazil', 'Argentina', 'Africa', 'Turkey', 'UAE', 'Call', 'Email', '2028']",2022-06-04,2022-06-05,nuhey.news
5997,Clearstream,Twitter API,Twitter,@MegNumbers Panama paper was a consortium but people like Denis Robert who revealed the Clearstream scandal was almost sent to ruin.,nan,@MegNumbers Panama paper was a consortium but people like Denis Robert who revealed the Clearstream scandal was almost sent to ruin.,negative,0.0,0.0,0.99,negative,0.0,0.0,0.99,True,English,"['Denis Robert', 'Clearstream scandal', 'consortium', 'people', 'Denis Robert', 'Clearstream scandal', 'consortium', 'people']",2022-06-03,2022-06-05,Unknown
6003,Deutsche Boerse,Google API,https://www.bollyinside.com/news/the-delivery-hero-food-delivery-man-outside-of-germanys-first-class-index,The Delivery Hero food delivery man outside of Germany‚Äôs first-class index,1 day ago,Food deliverer Delivery Hero will drop out of Germany‚Äôs blue chip stock index DAX supplanted by consumer goods creator Beiersdorf from June 20  stock market operator Deutsche Boerse said on Friday. A little more than a year in the wake of being consigned from the DAX  the Nivea cream producer and Hansaplast wound care Beiersdorf replaces Delivery Hero nicht  Deutsche Boerse said. However  there had been long discussions about the food delivery company‚Äôs DAX suitability  said CMC Markets analyst Konstantin Oldenburger.‚ÄúFor years  Delivery Hero has been writing losses and basically doesn‚Äôt operate any business or service in Germany it self ‚Äù Oldenburger said.News Summary:,neutral,0.17,0.79,0.04,negative,0.01,0.23,0.76,True,English,"['The Delivery Hero food delivery man', 'first-class index', 'Germany', 'CMC Markets analyst Konstantin Oldenburger', 'blue chip stock index DAX', 'consumer goods creator Beiersdorf', 'Food deliverer Delivery Hero', 'stock market operator', 'food delivery company', 'Nivea cream producer', 'Hansaplast wound care', 'DAX suitability', 'Deutsche Boerse', 'long discussions', 'News Summary', 'Germany', 'June', 'Friday', 'wake', 'years', 'losses', 'business', 'service']",2022-06-04,2022-06-05,bollyinside.com
6005,EuroNext,NewsApi.org,https://news.yahoo.com/russia-war-global-food-security-075200603.html,Russia‚Äôs war on global food security,Russian President Vladimir Putin‚Äôs war on Ukraine is also a war on global food security. In February 2022  Russia blockaded all of Ukraine‚Äôs Black Sea ports ...,David Beasley  the executive director of the United Nations World Food Programme (WFP)  recently warned  ‚ÄúWhen a country like Ukraine that grows enough food for 400 million people is out of the market  it creates market volatility  which we are now seeing.‚ÄùBeasley made clear how grave the crisis is as Russian forces preventing Ukraine‚Äôs exports from getting to market threaten to plunge vulnerable populations into peril. ‚ÄúTruly  failure to open those ports in the Odesa region will be a declaration of war on global food security ‚Äù said Beasley. ‚ÄúAnd it will result in famine and destabilization and mass migration around the world.‚ÄùIn recent years  Ukraine‚Äôs export revenues from both goods and services have surged  thanks to booming agricultural production and rising commodity prices. They soared from $124 billion in 2020 to a record of $166 billion in 2021  while Ukraine‚Äôs gross domestic product (GDP) was $200 billion. Meanwhile  the share of agriculture in Ukraine‚Äôs export revenues from goods increased from 26 percent in 2012 to 45 percent in 2020.Read also: Russia delivered 100 000 tons of stolen Ukrainian grain to SyriaRussia has further aggravated this food crisis by bombing and burning grain storage in the south and east of Ukraine  by stealing hundreds of thousands of tons of grain  and by exporting it on its own ships  primarily to its ally Syria.Russia‚Äôs war on Ukraine‚Äôs grain exports should not be allowed to continue. The collective West needs to open Ukraine‚Äôs Black Sea ports  primarily the major ports in Odesa  to mitigate the ongoing crisis in countries suffering from food insecurity  as well as enabling Ukraine to sell the twenty-eight million tons of grain it has in storage.Ukraine is a global granaryBefore communism  Ukraine was the granary of the world; since the privatization of agricultural land in 2000  it has become so again. Its grain production has skyrocketed  and Ukraine is now focusing on modern grains‚Äîcorn  wheat  soy  canola  and sunflower oil.Story continuesUkraine is a major producer of many grains. In 2021  it produced some eighty-six million tons of grain. The latest reliable statistics are for 2019 from the Food and Agriculture Organization (FAO) of the United Nations.In 2019  Ukraine produced 35.9 million tons of corn. It was the fifth-biggest grower of corn after the United States  China  Brazil  and Argentina  producing 3.1 percent of all corn in the world. Ukraine produced 28.4 million tons of wheat  or 3.7 percent of global production  ranking seventh in the world  after China  India  Russia  the United States  France  and Canada.Ukraine‚Äôs role as an exporter of grain is much greater because most of the other major producers are very large countries  such as China  India  the United States  Indonesia  and Brazil  which consume much of their produce themselves.Read also: List of Russian ships exporting Ukrainian grain given to Turkey  Dzhemilev saysIn 2019  42 percent of all global sunflower oil exports came from Ukraine  as did 16 percent of all corn exports  8.9 percent of all wheat exports  and 9.7 percent of all barley exports. Because of Ukraine‚Äôs swiftly expanding agriculture  the country‚Äôs role as a grain exporter has risen fast.Most attention is being devoted to wheat because it is crucial for economically developing countries‚Äô supplies of bread  a basic staple. With its steadily improving agriculture  Ukraine‚Äôs exports have risen in turn. For the year until July 2021  the US Department of Agriculture assessed Ukrainian exports of wheat at 23.5 million tons.These wheat exports were spread to many countries in Asia  the Middle East  and North Africa. The main recipients by quantity were Indonesia  Egypt  Pakistan  Bangladesh  Morocco  Turkey  Yemen  Tunisia  Libya  Lebanon  and the Philippines. These countries are most likely to suffer from a new shortfall of wheat.Corn is the second important grain export. Ukraine has nearly perfect conditions for growing corn  similar to those of the US states of Iowa and Illinois  and corn production has grown exponentially. For the year until July 2021  the US Department of Agriculture assessed Ukrainian exports of corn at thirty-four million tons.The corn exports went in quite different directions from the wheat exports  going to somewhat wealthier countries  because corn is mainly used for animal feed. In recent years  Ukraine‚Äôs main market has been China  which bought no less than 8.4 million tons of Ukraine‚Äôs corn exports in 2020‚Äì2021. Other major purchasers were Spain  the Netherlands  Egypt  and Iran.Officially  Russia closed vast expanses of the Black and the Azov Seas for civilian maritime traffic  under the pretext of naval exercises  for the period from February 13‚Äì19. It had no legal basis for this decision. Thus  Russia closed the access to all Ukraine‚Äôs ports from the Black Sea  and the ports have remained shut ever since. Russia has also mined them. Russian naval ships have hit at least ten commercial ships since Russia launched its assault  according to the International Maritime Organization. They sank one Estonian commercial ship. About eighty commercial ships have been caught in the Black Sea or the Sea of Azov for months. The risk to commercial shipping in the area has soared  and the cost of marine insurance in the Black Sea has skyrocketed as a result.A tight global grain marketIn recent years  the global grain market has tightened fast because of production problems in many parts of the world  which are largely connected with climate change. The two big positive exceptions have been Russia and Ukraine. As a result of a tightening global grain market  global prices have risen greatly. By and large  global wheat prices have doubled since early 2021. The Euronext Paris milling price of wheat has risen from about 200 euros per ton in early 2021 to 400 euros a ton at present.Food is a highly sensitive political issue. As politicians are anxious to keep food prices low  they want to keep scarce domestically produced grains at home  and shortages often provoke export bans.More than twenty countries have already imposed export bans on food  including important grain producers such as India and Indonesia. More countries are likely to follow  further aggravating the global shortage of grains.As the global grain market grows tighter  many traditional exporters prohibit exports to keep their domestic prices low  to avoid political tensions. But  as they prohibit exports  global grain prices rise further  and the economically weak countries that struggle to afford their vital grain imports suffer the most.How can Ukraine get its grain to market?Out of Ukraine‚Äôs total grain production of some eighty-six million tons in 2021  about twenty-eight million tons are stuck in Ukrainian ports because of the Russian naval blockade. Ukraine has limited storage available‚Äîand  after some time in storage  much of the grain perishes. Moreover  new sowing and other work require financing  and the Ukrainian farmers need to be able to sell their grain in order to acquire financing for the next year‚Äôs harvest.At the Stuttgart Group of Seven (G7) conference from May 12‚Äì14  Ukraine‚Äôs Minister of Agrarian Policy Mykola Solsky laid out the situation  saying  ‚ÄúDue to the blockade of Ukrainian seaports  7 million tons of wheat  14 million tons of corn  3 million tons of sunflower oil  and 3 million tons of sunflower meal and other crops have not entered the world market.‚Äù Usually  Ukraine would export 6‚Äì7 million tons a month through its Black Sea ports  but they are blocked  and the Russians offer no sign of easing up.Read also: Business community urges international organizations to help lift Russia‚Äôs blockade of Black Sea portsUkrainian exports fell by 58 percent and imports by 76 percent from March 2021 to March 2022  which reflects just how devastatingly Russian warfare has hindered much of the production and transportation of goods in Ukraine.Ukraine has no alternative seaports for its large grain volumes. Rail or truck transportation can take some volumes through Poland or Romania  to the Polish port of Gdansk  the Lithuanian port of Klaipeda  or the Romanian ports on the Danube River or the Black Sea. At present  these alternative routes can only manage about one-tenth of the demand  400 000‚Äì500 000 tons per month  but they can rise to 2 million tons per month  according to Ukrainian agricultural experts interviewed by the author  and the delays are substantial and costly. The delays are caused by both infrastructure bottlenecks and seemingly excessive border controls. The rail transportation is being impeded by Ukraine having broad track gauge (the distance between the two rails on a railway track)  matching railways in Russia  Belarus  and the Baltics  which are different from railways in Poland and Romania.The alternative transportation routes are cumbersome  small  and costly. Usually  the transportation of grain to a Black Sea port costs a Ukrainian grain producer about 10 percent of the price.Once there  one of the big international grain traders buys the grain and takes it over. Currently  the added cost to transport grain to Gdansk or Klaipeda adds about 30 percent. Considering that European grain prices have doubled in a year  that is not prohibitive  but the capacity remains tiny‚Äîwhatever Ukrainian exports make it to these ports are unlikely to make the difference needed to mitigate the global food crisis.Read also: Putin ‚Äòsignals‚Äô readiness to lift blockade of Ukrainian ports  exchange POWs  says Austrian chancellorThe only substantial option for the export of grain is through the Ukrainian Black Sea ports  primarily the Pivdenny and Odesa ports in the Odesa region. There is no viable alternative.Accusations of Russian destruction and plunderThe Kremlin has by no means ignored the global food crisis. To the contrary  it has decided to aggravate and exploit it. Ample Ukrainian sources report that the Russian military has intentionally bombed and burnt Ukrainian grain elevators  fertilizer stores  farming areas  and infrastructure.Russians have stolen grain on an industrial scale. Ukraine‚Äôs Deputy Agriculture Minister Taras Vysotskiy stated in early May that Russians had exported 441 000 tons of grain from the four occupied regions of Zaporizhia  Kherson  Donetsk  and Luhansk. They transported the stolen grain on trucks to Novorossiisk  the main Russian port on the Black Sea  or Sevastopol  the top Crimean port.Then  they ship the grain through the Bosporus to Mediterranean ports. Ports in Cyprus and Lebanon have reportedly turned down delivery of stolen grain  while Russia‚Äôs ally Syria accepts it. However  Vysotskiy states that only 1.5 million tons of grain was stored on newly occupied territory.Putin has a long history of personal involvement in major graft operations and is reportedly micromanaging elements of the war on Ukraine. Businessman and human-rights leader Bill Browder showed how such business is done in his investigation of the Sergei Magnitsky affair.Of the $230 million stolen from the Russian tax office  the Panama Papers showed that $800 000 had gone to President Putin himself  and Putin fought tooth and nail to defend the theft from his own government.Given Putin‚Äôs history and the big business of stealing and selling Ukraine‚Äôs grain  it is likely that these new operations are being organized at the highest level.Similarly  since 2014  Russian government-supported business has exported coal from illegally confiscated coal mines in occupied Donbas to Russia  Belarus  Poland  and Turkey  leading to legal cases in Poland and Turkey.This is part of the Putin government‚Äôs close cooperation with organized crime  which has been deeply detailed in recent books by Karen Dawisha  Bill Browder  Catherine Belton  and this author.How the Russian blockade of Ukraine‚Äôs Black Sea Ports can be endedSince early February  Russia has blocked all of Ukraine‚Äôs seaports without any legal excuse or recourse. In the first month of the war alone  the Russian navy attacked at least eight civilian commercial freight ships  and has caused one Estonian freight ship to sink  likely from a mine. These disturbing events have received relatively little international attention.Russia has mined all the Ukrainian ports with hundreds of mines. The three NATO countries around the Black Sea‚ÄîBulgaria  Romania and Turkey‚Äîhave all reported that loose mines have reached their territorial waters.For too long  the undeclared Russian blockade of all Ukrainian Black Sea ports has attracted little international attention in spite of its many negative effects and the absence of a legal case.Since half of Ukraine‚Äôs exports are grain  the blockade deprived Ukraine of roughly half its exports earnings  adding a serious economic dimension to the Kremlin‚Äôs full-scale war on Ukraine. Combined with the potential effect of starving approximately forty-seven million people  the seriousness of Russia‚Äôs blockade cannot be understated.At long last  the West appears to be waking up to this disaster  and has started to consider doing something. From May 12‚Äì14  the foreign ministers of the G7 countries warned that ‚ÄúRussia‚Äôs war of aggression has generated one of the most severe food and energy crises in recent history which now threatens those most vulnerable across the globe‚Ä¶We are determined to accelerate a coordinated multilateral response to preserve global food security and stand by our most vulnerable partners in this respect.‚ÄùBut how can this be done? Moscow correctly assesses that the blockade is a major blow to the Ukrainian economy and a potent tool in its war to cripple Ukraine‚Äîso how can the US and its allies make the Kremlin stand down?The first step is to rally international support to lift the blockade. Moscow has taken comfort from the fact that non-aligned nations have not come out strongly against its aggression in Ukraine.But some of the most impacted victims of the Kremlin-induced food shortage are prominent nations like Egypt and Indonesia. The G-7 should begin a massive public diplomacy campaign to ensure that key nations in Africa  Latin America  the Middle East  and South Asia understand the origins of the food shortage and the obvious solution‚Äîto open shipping from Odesa  at a minimum for vital food supplies.The aim would be to bring this issue to the UN General Assembly for a resolution calling for an end to the naval blockade in the Black Sea  at least on food. This effort will force Moscow to pay a greater political price for the blockade.At the same time  the US should explore creating a coalition of willing states to establish a humanitarian maritime channel to Odesa to escort food products out of dangerous waters in the Black Sea. This maritime channel could also be used to deliver crucial humanitarian aid to Ukraine. The group should include NATO allies and especially Turkey  as well as interested partners and key non-aligned states that import grain from Ukraine and that have a strong navy.Turkey is essential to include to ensure that there is no problem with the 1936 Montreux Convention  which governs the passage of vessels through the Bosporus. Given its strong navy and history in successfully standing up to Russian military brinksmanship  Turkey would be valuable in a key role for any international coalition.Egypt is a major grain-importing country impacted by this crisis with a navy that could assist with demining.While this approach contains risk of a confrontation with Russia  it is worth noting that the US navy delivered humanitarian aid to Georgia during the 2008 war while avoiding any serious escalation with Moscow. Creating a large international task force would raise the risks to Moscow of using force to deny access to and from Odesa.Read also: Kuleba and Podolyak respond to Russia's ‚Äòblackmail‚Äô proposal for corridor for grain exportsThis proposal is already gaining traction. On May 22  Lithuanian Foreign Minister Gabrielius Landsbergis argued that ‚ÄúThe countries who consider the looming global food crisis a serious challenge‚Ä¶should guarantee a safe passage of ships from Odesa across the Black Sea to the Bosporus.‚ÄùLandsbergis went on to affirm that guaranteeing food supplies is not an escalation  and that urgent action is required to avert a deeper crisis.In parallel  the West needs to reinforce Ukraine‚Äôs naval defense  notably with the delivery of potent anti-ship missiles and mine-sweeping facilities.Denmark is already moving in this direction  pledging the delivery of Harpoon anti-ship missile systems to Ukraine. These systems will bolster Ukraine‚Äôs ability to defend against Russia‚Äôs Black Sea Fleet  but could take months to train on and integrate into the country‚Äôs coastal defense system. Further deliveries of these systems should take place immediately.Finally  the US  the EU  and other partners from around the world should consider possible economic measures to force Moscow to end the blockade. This could include an embargo on all Kremlin shipping. It might also include sanctions on all insurers for Russian shipping.This broad range approach holds open the door to ending the blockade but certainly increases the price to Moscow of continuing it and will add new nations to the list of those who oppose Putin‚Äôs war on Ukraine.Ukraine‚Äôs resistance to Russia‚Äôs war of aggression has seen remarkable success. But  with the war likely to continue for the foreseeable future  the deeply destabilizing impact on the global economy appears set to continue as well  with tens of millions of people in the Global South being plunged into mass starvation.To reduce the risk of further mass hunger and the ensuing political destabilization  global powers must make it a priority to urgently open Ukraine‚Äôs ports for shipping.The operations required to fulfill this mission have successful precedent and can be accomplished without a serious escalation in this conflict. Russia‚Äôs war on Ukraine has sparked sea changes in global politics on a historic scale.As the West grapples with how to move forward  addressing Russia‚Äôs culpability in exploiting a global food crisis‚Äîand mitigating the damage‚Äîis essential.This story was first published by the Atlantic Council. NV is republishing it with permission.,negative,0.05,0.29,0.66,mixed,0.1,0.12,0.78,True,English,"['global food security', 'Russia', 'war', 'United Nations World Food Programme', 'second important grain export', 'global sunflower oil exports', 'rising commodity prices', 'gross domestic product', 'The collective West', 'latest reliable statistics', 'civilian maritime traffic', 'other major producers', 'Other major purchasers', 'International Maritime Organization', 'global food security', 'ten commercial ships', 'developing countries‚Äô supplies', 'booming agricultural production', 'twenty-eight million tons', 'eighty-six million tons', 'thirty-four million tons', 'Russian naval ships', 'Black Sea ports', 'global production', 'export revenues', 'United States', 'Russian ships', 'enough food', 'food insecurity', 'agricultural land', 'naval exercises', '35.9 million tons', '28.4 million tons', '23.5 million tons', '400 million people', 'Russian forces', 'global granary', 'food crisis', 'major ports', 'grain production', 'executive director', 'vulnerable populations', 'mass migration', 'recent years', 'modern grains', 'many grains', 'biggest grower', 'barley exports', 'Most attention', 'basic staple', 'US Department', 'Ukrainian exports', 'North Africa', 'main recipients', 'new shortfall', 'perfect conditions', 'US states', 'different directions', 'animal feed', 'vast expanses', 'Azov Seas', 'legal basis', 'Agriculture Organization', 'large countries', 'many countries', 'wealthier countries', 'Ukrainian grain', 'grain exports', 'ongoing crisis', 'corn production', 'market volatility', 'Odesa region', 'Middle East', 'main market', 'corn exports', 'growing corn', 'wheat exports', 'David Beasley', 'expanding agriculture', 'grain storage', 'grain exporter', '100,000 tons', 'WFP', 'country', 'Ukraine', 'peril', 'failure', 'declaration', 'war', 'famine', 'destabilization', 'goods', 'services', 'record', 'GDP', 'share', '26 percent', '45 percent', 'Syria', 'south', 'hundreds', 'thousands', 'ally', 'communism', 'privatization', 'soy', 'canola', 'Story', 'FAO', 'China', 'Brazil', 'Argentina', '3.1 percent', '3.7 percent', 'India', 'France', 'Canada', 'role', 'Indonesia', 'List', 'Turkey', 'Dzhemilev', '42 percent', '16 percent', '8.9 percent', '9.7 percent', 'bread', 'turn', 'July', 'Asia', 'quantity', 'Egypt', 'Pakistan', 'Bangladesh', 'Morocco', 'Yemen', 'Tunisia', 'Libya', 'Lebanon', 'Philippines', 'Iowa', 'Illinois', 'less', 'Spain', 'Netherlands', 'Iran', 'pretext', 'period', 'February', 'decision', 'access', 'assault']",2022-06-04,2022-06-05,news.yahoo.com
6014,EuroNext,Twitter API,Twitter,#Euronext new #ESG Guidelines for listed companies https://t.co/JLpxKG1wJz,nan,#Euronext new #ESG Guidelines for listed companies https://t.co/JLpxKG1wJz,neutral,0.01,0.97,0.02,neutral,0.01,0.97,0.02,True,English,"['listed companies', 'JLpxKG1wJz', 'listed companies', 'JLpxKG1wJz']",2022-06-04,2022-06-05,Unknown
6015,EuroNext,Twitter API,Twitter,Other European markets lower on Friday  06/03/2022: Euronext 100 -0.19% at 1 235.19  lower for the week  Euro Stoxx‚Ä¶ https://t.co/CqQ5rwAR07,nan,Other European markets lower on Friday  06/03/2022: Euronext 100 -0.19% at 1 235.19  lower for the week  Euro Stoxx‚Ä¶ https://t.co/CqQ5rwAR07,neutral,0.02,0.9,0.08,neutral,0.02,0.9,0.08,True,English,"['Other European markets', 'Euro Stoxx', 'Friday', 'Euronext', 'week', 'CqQ5rwAR07', 'Other European markets', 'Euro Stoxx', 'Friday', 'Euronext', 'week', 'CqQ5rwAR07']",2022-06-04,2022-06-05,Unknown
6016,EuroNext,Twitter API,Twitter,#Airliquide : Voting Rights [ https://t.co/xB1NzVK71M ] Air Liquide is listed on the Euronext #Paris #Stock exchang‚Ä¶ https://t.co/6WVu69VEks,nan,#Airliquide : Voting Rights [ https://t.co/xB1NzVK71M ] Air Liquide is listed on the Euronext #Paris #Stock exchang‚Ä¶ https://t.co/6WVu69VEks,neutral,0.02,0.97,0.01,neutral,0.02,0.97,0.01,True,English,"['Voting Rights', 'Air Liquide', 'Stock exchang', 'xB1NzVK71M', 'WVu69VEks', 'Voting Rights', 'Air Liquide', 'Stock exchang', 'xB1NzVK71M', 'WVu69VEks']",2022-06-03,2022-06-05,Unknown
6017,Euroclear,Google API,https://publicwire.com/we-need-new-financial-pipes/,We need new financial pipes,18 hours ago,Manmohan Singh is a senior economist at the IMF. The views below are his own  rather than that of the IMF or its executive board.Every year around April I go through the annual reports of the big banks. It‚Äôs a fascinating exercise. But the real gold nuggets are often found in the footnotes  which most analysts never read.The latest numbers indicate that ‚Äúcollateral velocity‚Äù ‚Äî a measure of how quickly and smoothly collateral moves around the financial system ‚Äî has started slowing again.That indicates a need to augment the current financial plumbing  and raises a few issues that warrant attention from policymakers.First  some background. Collateral velocity is simply the ratio of the total pledged collateral received by the large banks  divided by the primary collateral sourced from reverse repos  securities borrowing  prime brokerage and derivative margin. This ratio measures the reuse of collateral due to financial intermediation between banks and non-banks  also known as ‚Äúcollateral chains‚Äù.For global banks that are active in peddling pledged collateral globally  there are two primary sources of collateral that form the basis of the bank/non-bank nexus  and the market plumbing: hedge funds and other types of institutional investors.For example  in 2007 about $3.4tn of ‚Äúsource collateral‚Äù was provided by hedge funds (via their repo and prime brokerage funding)  securities lending by pension funds and insurers  and via derivative margins. Given the overall pledged collateral of $10tn  this meant an overall collateral velocity (or reuse rate) of about 3.The original estimates of collateral velocity were first calculated in 2011. Researchers from Bank of England  Dutch Central Bank  Reserve Bank of Australia  and recently Bundesbank  and public-and-private regulators  (FSB and DTCC etc) have since been investigating this topic  including several working groups at BIS.As you might expect  a lot has changed since 2007  with the disappearance of Lehman Brothers and Bear Stearns  the reshuffling of business models by UBS  Credit Suisse and Deutsche Bank  and the rise of JPMorgan and Barclays. The latest data is in green-and-white bars below.Although dealers adapted to the post-Basel regulatory era and balance-sheet space constraints  re-use capacity has maxed out in recent years. Despite an increase in the sources of overall pledged collateral  balance sheet constraints limit only reuse in markets that are more profitable ‚Äî for example  prime brokerage transactions are preferred over repo.Changes in hedge fund strategies have been the primary drivers of the altered landscape  as banks have worked to accommodate their customers‚Äô preferences. The size of the hedge fund industry has grown above $4tn of assets under management  but it is important to understand their footprint (leverage) and their choice of funding.In the period 2019/20 we saw a shift from equity strategies (in prime brokerage) to fixed income strategies (in repo); then a reversal towards prime brokerage after the March 2020 crisis. Leverage also reshuffles with such strategies (repo is higher leverage than equity strategies).The initial post-2008 slump in collateral velocity was caused by a spike in counterparty risk aversion between large banks in the aftermath of Lehman Brothers‚Äôs demise. But it has remained subdued ever since  despite increasing sources of collateral in recent years.Factors like the European crisis  quantitative easing (central bank bond purchases restricted the availability of good collateral) and regulations that now restricted dealer banks‚Äô intermediation capacity have had a big impact. After ticking up a little from the post-crisis doldrums  the collateral velocity fell back to 2.1 last year.Dealer balance sheet constraints and the collateral reuse metric are a harbinger for market plumbing issues. For example  the debt pipeline is likely to be sizeable relative to dealer balance sheet capacity to arrange transactions in all collateral markets (like repos/sec-lending/prime brokerage/derivatives). This is especially true in the US.If balance sheets are constrained  prime brokerage and derivatives transactions are generally more profitable per unit of balance sheet  although banks continue to seek creative netting solutions (like FICC) to make repo attractive.But the interest rate cycle is turning. Collateral constraints in some jurisdiction (such as the eurozone) mean we will need to revisit dealer balance sheet constraints  as repo markets will need to move in tandem with rate hikes. Basically  the ‚Äúold pipes‚Äù are maxed out  so new pipes are needed to augment the traditional ones  and bring the global financial plumbing into the new century.As a result  there are a few issues that warrant attention on the policy front:‚Ä¢ If new pipes are not forthcoming  we may need regulatory or central bank intervention to prevent unavoidable systemic risk. But in the the aftermath of the financial crisis and the Covid-19 pandemic  the central bank footprint in market is already large.‚Ä¢ Inter-operability  including tri-party links  is crucial to mobilise collateral. Global custodians such as Euroclear  Bank of New York or Clearstream ‚Äî often called ‚ÄúInternational Central Securities Depositories‚Äù ‚Äî are trying to enhance links with country-specific CSDs  but local laws often hinder such ties.‚Ä¢ Tokenisation maybe a silver lining on the horizon. Frictionless collateral with instant  realtime settlement can increase the velocity of collateral  if the new technology can work within the regulatory parameters.This post was originally published on this site,neutral,0.13,0.59,0.28,mixed,0.08,0.21,0.71,True,English,"['new financial pipes', 'central bank bond purchases', 'Dealer balance sheet constraints', 'dealer balance sheet capacity', 'balance-sheet space constraints', 'real gold nuggets', 'initial post-2008 slump', 'counterparty risk aversion', 'creative netting solutions', 'unavoidable systemic risk', 'Dutch Central Bank', 'central bank intervention', 'hedge fund industry', 'interest rate cycle', 'fixed income strategies', 'current financial plumbing', 'post-Basel regulatory era', 'central bank footprint', 'hedge fund strategies', 'global financial plumbing', 'two primary sources', 'banks‚Äô intermediation capacity', 'prime brokerage funding', 'prime brokerage transactions', 'collateral reuse metric', 'market plumbing issues', 'overall collateral velocity', 'balance sheets', 're-use capacity', 'Collateral constraints', 'financial intermediation', 'Reserve Bank', 'Deutsche Bank', 'hedge funds', 'financial system', 'financial crisis', 'primary drivers', 'rate hikes', 'equity strategies', 'global banks', 'primary collateral', 'reuse rate', 'Manmohan Singh', 'senior economist', 'executive board', 'annual reports', 'fascinating exercise', 'most analysts', 'latest numbers', 'derivative margin', 'bank/non-bank nexus', 'other types', 'institutional investors', 'pension funds', 'original estimates', 'private regulators', 'Lehman Brothers', 'Bear Stearns', 'business models', 'Credit Suisse', 'latest data', 'white bars', 'recent years', 'customers‚Äô preferences', 'March 2020 crisis', 'increasing sources', 'European crisis', 'quantitative easing', 'big impact', 'post-crisis doldrums', 'debt pipeline', 'lending/prime brokerage/derivatives', 'derivatives transactions', 'old pipes', 'new pipes', 'new century', 'policy front', 'Covid-19 pandemic', 'collateral moves', 'collateral chains', 'source collateral', 'good collateral', 'big banks', 'large banks', 'reverse repos', 'securities borrowing', 'collateral markets', 'repo markets', 'IMF', 'views', 'April', 'footnotes', 'measure', 'need', 'attention', 'policymakers', 'background', 'ratio', 'total', 'basis', 'example', 'insurers', 'Researchers', 'England', 'Australia', 'Bundesbank', 'public', 'FSB', 'DTCC', 'topic', 'several', 'groups', 'BIS', 'lot', 'disappearance', 'reshuffling', 'UBS', 'rise', 'JPMorgan', 'Barclays', 'green', 'dealers', 'increase', 'Changes', 'landscape', 'size', 'assets', 'management', 'leverage', 'choice', 'period', 'shift', 'reversal', 'spike', 'aftermath', 'demise', 'Factors', 'availability', 'regulations', 'harbinger', 'unit', 'FICC', 'jurisdiction', 'eurozone', 'tandem', 'traditional', 'result', 'Inter-operability']",2022-06-03,2022-06-05,publicwire.com
6018,Euroclear,Twitter API,Twitter,Stock Question: Owned by Euroclear what‚Äôs the name of the U.K settlement system?,nan,Stock Question: Owned by Euroclear what‚Äôs the name of the U.K settlement system?,neutral,0.01,0.97,0.02,neutral,0.01,0.97,0.02,True,English,"['U.K settlement system', 'Stock Question', 'Euroclear', 'name', 'U.K settlement system', 'Stock Question', 'Euroclear', 'name']",2022-06-05,2022-06-05,Unknown
6019,Clearstream,Google API,https://industrialit.com.au/peripheral-vascular-devices-market-size-by-share-growth-scope-and-forecast/,Peripheral Vascular Devices Market Size 2022 Booming Across the Globe by Share  Growth Size  Scope  Key Segments and Forecast to 2029 ‚Äì Industrial IT,1 day ago,New Jersey  United States ‚Äì The Global Peripheral Vascular Devices Market Report examines the present situation of the global Peripheral Vascular Devices Market and industry in great detail. All necessary data or information  such as market terminologies  concepts  segmentation  key players  and other critical insights  are included in the study. Profiles of the companies  executive descriptions  and other relevant data are also presented.To enhance the Global Peripheral Vascular Devices Market report more informative and valuable for businesses  VM Reports experts have provided a range of insights. The research includes a SWOT analysis  which helps businesses comprehend their strengths  weaknesses  opportunities  and threats in a challenging market.Get Full PDF Sample Copy of Report: (Including Full TOC  List of Tables & Figures  Chart) @ https://www.verifiedmarketreports.com/download-sample/?rid=41284(Use Company eMail ID to Get Higher Priority)A portion is also devoted to major players and their ambitions  such as acquisitions  mergers  and so on. Multiple perspectives  personal interviews  and surveys were used to compile the data for the Global Peripheral Vascular Devices Market research. The professionals at VM Reports have prepared a Global Peripheral Vascular Devices Market research report that is packed with clarity  accuracy  and relevant data. The information in the report is accurate and trustworthy  with no redundancies or omissions.Prominent Key players of the Peripheral Vascular Devices market survey report:Medtronic  Angiomed GmbH  Co. Medizintechnik KG  Abbott Laboratories Vascular Enterprises Limited  Terumo Corporation  ENDOLOGIX  Bolton Medical  Jotec GmbH  ClearStream Technologies Ltd.  Aesculap AG  Boston Scientific Corporation  curative medical devices gmbh  Lepu  Microport  BioteqData is collected by VM Reports specialists employing a mix of qualitative and quantitative data approaches. Both primary and secondary data techniques were utilized to build an engaging report that the organization and clients may use whenever they need it. The study will also look at key alliances  initiatives  and global partnerships that are projected to have a global impact on market dynamics shortly.Key Segments Covered in Peripheral Vascular Devices Market ‚Äì Industry Analysis By Types  Applications  and Regions:Peripheral Vascular Devices Market ‚Äì Types Outlook (Revenue  USD Million  2017 ‚Äì 2029)‚Ä¢ Peripheral vascular stents‚Ä¢ PTA balloon catheter‚Ä¢ Embolic protection device‚Ä¢ Aortic stent graft‚Ä¢ Surgical artificial transplantPeripheral Vascular Devices Market ‚Äì Applications Outlook (Revenue  USD Million  2017 ‚Äì 2029)‚Ä¢ The treatment of peripheral blood vessels damaged‚Ä¢ The treatment of peripheral blood vessels blockageFor More Information or Query or Customization Before Buying  Visit @ https://www.verifiedmarketreports.com/product/global-peripheral-vascular-devices-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024/Peripheral Vascular Devices Market Report ScopeATTRIBUTES DETAILS ESTIMATED YEAR 2022 BASE YEAR 2021 FORECAST YEAR 2029 HISTORICAL YEAR 2020 UNIT Value (USD Million/Billion) SEGMENTS COVERED Types  Applications  End-Users  and more. REPORT COVERAGE Revenue Forecast  Company Ranking  Competitive Landscape  Growth Factors  and Trends BY REGION North America  Europe  Asia Pacific  Latin America  Middle East and Africa CUSTOMIZATION SCOPE Free report customization (equivalent up to 4 analysts working days) with purchase. Addition or alteration to country  regional & segment scope.Regional Analysis of the Peripheral Vascular Devices Market:The Peripheral Vascular Devices Market research report details the ongoing market trends  development outlines  and several research methodologies. It illustrates the key factors that directly manipulate the Market  for instance  production strategies  development platforms  and product portfolio. According to our researchers  even minor changes within the product profiles could result in huge disruptions to the above-mentioned factors.‚ûõ North America (United States  Canada  and Mexico)‚ûõ Europe (Germany  France  UK  Russia  and Italy)‚ûõ Asia-Pacific (China  Japan  Korea  India  and Southeast Asia)‚ûõ South America (Brazil  Argentina  Colombia  etc.)‚ûõ Middle East and Africa (Saudi Arabia  UAE  Egypt  Nigeria  and South Africa)What insights does the Peripheral Vascular Devices Market report provide to the readers?‚ûú Peripheral Vascular Devices fragmentation on the basis of product type  end-use  and region‚ûú Comprehensive assessment of upstream starting materials  downstream demand  and present market landscape‚ûú Collaborations  R&D projects  acquisitions  and product launches of each Peripheral Vascular Devices player‚ûú Various regulations imposed by the governments on the consumption of Peripheral Vascular Devices in detail‚ûú Impact of modern technologies  such as big data & analytics  artificial intelligence  and social media platforms on the Peripheral Vascular DevicesGet a Discount On The Purchase Of This Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=41284Visualize Peripheral Vascular Devices Market using Verified Market Intelligence:-Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20 000+ emerging & niche markets  helping you make critical revenue-impacting decisions for a brilliant future.VMI provides a holistic overview and global competitive landscape with respect to Region  Country  and Segment  and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor  Sales & Marketing  R&D  and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.Visualize Peripheral Vascular Devices Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/Top Trending ReportsGlobal Sleep Apnea Diagnostic Devices Market Size And ForecastGlobal Pen Needles Market Size And ForecastGlobal Cardiac Pacing Market Size And ForecastGlobal Peripheral Vascular Devices Market Size And ForecastGlobal Monoclonal Antibody Diagnostic Reagents Market Size And ForecastGlobal Sclerotherapy Market Size And ForecastGlobal Liraglutide Market Size And ForecastGlobal Gelatin Capsule Market Size And ForecastGlobal Blood Collection Tubes Market Size And ForecastGlobal Avian Influenza Vaccines Market Size And ForecastAbout Us: Verified Market ReportsVerified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.Our 250 Analysts and SME‚Äôs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25 000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques  superior research methodology  expertise  and years of collective experience to produce informative and accurate research.Our research spans over a multitude of industries including Energy  Technology  Manufacturing and Construction  Chemicals and Materials  Food and Beverages etc. Having serviced many Fortune 2000 organizations  we bring a rich and reliable experience that covers all kinds of research needs.Contact us:Mr. Edwyne FernandesUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768Email: [email protected]Website: ‚Äì https://www.verifiedmarketreports.com/,neutral,0.01,0.98,0.01,mixed,0.41,0.16,0.43,True,English,"['Peripheral Vascular Devices', 'Market Size', 'Growth Size', 'Key Segments', 'Industrial IT', 'Globe', 'Share', 'Scope', 'Forecast', 'The Global Peripheral Vascular Devices Market Report', 'Global Peripheral Vascular Devices Market research report', 'Peripheral Vascular Devices market survey report', 'Peripheral Vascular Devices Market Report Scope', 'Africa CUSTOMIZATION SCOPE Free report customization', 'Abbott Laboratories Vascular Enterprises Limited', 'The Peripheral Vascular Devices', 'Peripheral Vascular Devices fragmentation', 'Peripheral Vascular Devices player', 'HISTORICAL YEAR 2020 UNIT Value', 'peripheral blood vessels blockage', 'BASE YEAR 2021 FORECAST YEAR', 'curative medical devices gmbh', 'Full PDF Sample Copy', 'REPORT COVERAGE Revenue Forecast', 'Peripheral vascular stents', 'several research methodologies', 'ongoing market trends', 'present market landscape', 'Co. Medizintechnik KG', 'PTA balloon catheter', 'Embolic protection device', 'Aortic stent graft', 'upstream starting materials', 'R&D projects', 'Company eMail ID', 'ClearStream Technologies Ltd.', 'Boston Scientific Corporation', 'Surgical artificial transplant', 'social media platforms', 'VM Reports experts', 'VM Reports specialists', 'quantitative data approaches', 'secondary data techniques', 'Prominent Key players', 'SEGMENTS COVERED Types', 'global partnerships', 'other relevant data', 'REGION North America', 'segment scope', 'engaging report', 'global impact', 'The Purcha', 'market terminologies', 'challenging market', 'market dynamics', 'Full TOC', 'Bolton Medical', 'South Africa', 'Key Segments', 'Angiomed GmbH', 'Jotec GmbH', 'present situation', 'Terumo Corporation', 'Company Ranking', 'Competitive Landscape', 'development platforms', 'modern technologies', 'artificial intelligence', 'major players', 'necessary data', 'Bioteq Data', 'Latin America', 'South America', 'big data', 'key alliances', 'New Jersey', 'United States', 'executive descriptions', 'SWOT analysis', 'Higher Priority', 'Multiple perspectives', 'personal interviews', 'Aesculap AG', 'Types Outlook', 'ATTRIBUTES DETAILS', 'Asia Pacific', 'Middle East', 'development outlines', 'production strategies', 'product portfolio', 'minor changes', 'huge disruptions', 'Southeast Asia', 'Saudi Arabia', 'product type', 'Comprehensive assessment', 'downstream demand', 'product launches', 'Various regulations', 'key factors', 'Growth Factors', 'great detail', 'Industry Analysis', 'Regional Analysis', 'product profiles', 'critical insights', 'Applications Outlook', 'More Information', 'concepts', 'segmentation', 'study', 'companies', 'businesses', 'range', 'strengths', 'weaknesses', 'opportunities', 'threats', 'Tables', 'Figures', 'Chart', 'verifiedmarketreports', 'portion', 'ambitions', 'acquisitions', 'mergers', 'surveys', 'professionals', 'clarity', 'accuracy', 'redundancies', 'omissions', 'Medtronic', 'ENDOLOGIX', 'Lepu', 'Microport', 'mix', 'qualitative', 'primary', 'organization', 'clients', 'initiatives', 'Regions', 'treatment', 'Query', 'Buying', 'global-peripheral-vascular-devices-market', 'Billion', 'End-Users', 'Europe', '4 analysts', 'purchase', 'Addition', 'alteration', 'instance', 'researchers', 'Canada', 'Mexico', 'Germany', 'France', 'UK', 'Russia', 'Italy', 'Asia-Pacific', 'China', 'Japan', 'Korea', 'India', 'Brazil', 'Argentina', 'Colombia', 'UAE', 'Egypt', 'Nigeria', 'readers', 'basis', 'Collaborations', 'governments', 'consumption', 'analytics', 'Discount']",2022-06-05,2022-06-05,industrialit.com.au
6020,Clearstream,Google API,https://publicwire.com/we-need-new-financial-pipes/,We need new financial pipes,18 hours ago,Manmohan Singh is a senior economist at the IMF. The views below are his own  rather than that of the IMF or its executive board.Every year around April I go through the annual reports of the big banks. It‚Äôs a fascinating exercise. But the real gold nuggets are often found in the footnotes  which most analysts never read.The latest numbers indicate that ‚Äúcollateral velocity‚Äù ‚Äî a measure of how quickly and smoothly collateral moves around the financial system ‚Äî has started slowing again.That indicates a need to augment the current financial plumbing  and raises a few issues that warrant attention from policymakers.First  some background. Collateral velocity is simply the ratio of the total pledged collateral received by the large banks  divided by the primary collateral sourced from reverse repos  securities borrowing  prime brokerage and derivative margin. This ratio measures the reuse of collateral due to financial intermediation between banks and non-banks  also known as ‚Äúcollateral chains‚Äù.For global banks that are active in peddling pledged collateral globally  there are two primary sources of collateral that form the basis of the bank/non-bank nexus  and the market plumbing: hedge funds and other types of institutional investors.For example  in 2007 about $3.4tn of ‚Äúsource collateral‚Äù was provided by hedge funds (via their repo and prime brokerage funding)  securities lending by pension funds and insurers  and via derivative margins. Given the overall pledged collateral of $10tn  this meant an overall collateral velocity (or reuse rate) of about 3.The original estimates of collateral velocity were first calculated in 2011. Researchers from Bank of England  Dutch Central Bank  Reserve Bank of Australia  and recently Bundesbank  and public-and-private regulators  (FSB and DTCC etc) have since been investigating this topic  including several working groups at BIS.As you might expect  a lot has changed since 2007  with the disappearance of Lehman Brothers and Bear Stearns  the reshuffling of business models by UBS  Credit Suisse and Deutsche Bank  and the rise of JPMorgan and Barclays. The latest data is in green-and-white bars below.Although dealers adapted to the post-Basel regulatory era and balance-sheet space constraints  re-use capacity has maxed out in recent years. Despite an increase in the sources of overall pledged collateral  balance sheet constraints limit only reuse in markets that are more profitable ‚Äî for example  prime brokerage transactions are preferred over repo.Changes in hedge fund strategies have been the primary drivers of the altered landscape  as banks have worked to accommodate their customers‚Äô preferences. The size of the hedge fund industry has grown above $4tn of assets under management  but it is important to understand their footprint (leverage) and their choice of funding.In the period 2019/20 we saw a shift from equity strategies (in prime brokerage) to fixed income strategies (in repo); then a reversal towards prime brokerage after the March 2020 crisis. Leverage also reshuffles with such strategies (repo is higher leverage than equity strategies).The initial post-2008 slump in collateral velocity was caused by a spike in counterparty risk aversion between large banks in the aftermath of Lehman Brothers‚Äôs demise. But it has remained subdued ever since  despite increasing sources of collateral in recent years.Factors like the European crisis  quantitative easing (central bank bond purchases restricted the availability of good collateral) and regulations that now restricted dealer banks‚Äô intermediation capacity have had a big impact. After ticking up a little from the post-crisis doldrums  the collateral velocity fell back to 2.1 last year.Dealer balance sheet constraints and the collateral reuse metric are a harbinger for market plumbing issues. For example  the debt pipeline is likely to be sizeable relative to dealer balance sheet capacity to arrange transactions in all collateral markets (like repos/sec-lending/prime brokerage/derivatives). This is especially true in the US.If balance sheets are constrained  prime brokerage and derivatives transactions are generally more profitable per unit of balance sheet  although banks continue to seek creative netting solutions (like FICC) to make repo attractive.But the interest rate cycle is turning. Collateral constraints in some jurisdiction (such as the eurozone) mean we will need to revisit dealer balance sheet constraints  as repo markets will need to move in tandem with rate hikes. Basically  the ‚Äúold pipes‚Äù are maxed out  so new pipes are needed to augment the traditional ones  and bring the global financial plumbing into the new century.As a result  there are a few issues that warrant attention on the policy front:‚Ä¢ If new pipes are not forthcoming  we may need regulatory or central bank intervention to prevent unavoidable systemic risk. But in the the aftermath of the financial crisis and the Covid-19 pandemic  the central bank footprint in market is already large.‚Ä¢ Inter-operability  including tri-party links  is crucial to mobilise collateral. Global custodians such as Euroclear  Bank of New York or Clearstream ‚Äî often called ‚ÄúInternational Central Securities Depositories‚Äù ‚Äî are trying to enhance links with country-specific CSDs  but local laws often hinder such ties.‚Ä¢ Tokenisation maybe a silver lining on the horizon. Frictionless collateral with instant  realtime settlement can increase the velocity of collateral  if the new technology can work within the regulatory parameters.This post was originally published on this site,neutral,0.13,0.59,0.28,mixed,0.08,0.21,0.71,True,English,"['new financial pipes', 'central bank bond purchases', 'Dealer balance sheet constraints', 'dealer balance sheet capacity', 'balance-sheet space constraints', 'real gold nuggets', 'initial post-2008 slump', 'counterparty risk aversion', 'creative netting solutions', 'unavoidable systemic risk', 'Dutch Central Bank', 'central bank intervention', 'hedge fund industry', 'interest rate cycle', 'fixed income strategies', 'current financial plumbing', 'post-Basel regulatory era', 'central bank footprint', 'hedge fund strategies', 'global financial plumbing', 'two primary sources', 'banks‚Äô intermediation capacity', 'prime brokerage funding', 'prime brokerage transactions', 'collateral reuse metric', 'market plumbing issues', 'overall collateral velocity', 'balance sheets', 're-use capacity', 'Collateral constraints', 'financial intermediation', 'Reserve Bank', 'Deutsche Bank', 'hedge funds', 'financial system', 'financial crisis', 'primary drivers', 'rate hikes', 'equity strategies', 'global banks', 'primary collateral', 'reuse rate', 'Manmohan Singh', 'senior economist', 'executive board', 'annual reports', 'fascinating exercise', 'most analysts', 'latest numbers', 'derivative margin', 'bank/non-bank nexus', 'other types', 'institutional investors', 'pension funds', 'original estimates', 'private regulators', 'Lehman Brothers', 'Bear Stearns', 'business models', 'Credit Suisse', 'latest data', 'white bars', 'recent years', 'customers‚Äô preferences', 'March 2020 crisis', 'increasing sources', 'European crisis', 'quantitative easing', 'big impact', 'post-crisis doldrums', 'debt pipeline', 'lending/prime brokerage/derivatives', 'derivatives transactions', 'old pipes', 'new pipes', 'new century', 'policy front', 'Covid-19 pandemic', 'collateral moves', 'collateral chains', 'source collateral', 'good collateral', 'big banks', 'large banks', 'reverse repos', 'securities borrowing', 'collateral markets', 'repo markets', 'IMF', 'views', 'April', 'footnotes', 'measure', 'need', 'attention', 'policymakers', 'background', 'ratio', 'total', 'basis', 'example', 'insurers', 'Researchers', 'England', 'Australia', 'Bundesbank', 'public', 'FSB', 'DTCC', 'topic', 'several', 'groups', 'BIS', 'lot', 'disappearance', 'reshuffling', 'UBS', 'rise', 'JPMorgan', 'Barclays', 'green', 'dealers', 'increase', 'Changes', 'landscape', 'size', 'assets', 'management', 'leverage', 'choice', 'period', 'shift', 'reversal', 'spike', 'aftermath', 'demise', 'Factors', 'availability', 'regulations', 'harbinger', 'unit', 'FICC', 'jurisdiction', 'eurozone', 'tandem', 'traditional', 'result', 'Inter-operability']",2022-06-03,2022-06-05,publicwire.com
6021,Deutsche Boerse,Twitter API,Twitter,I found you an Oversold RSI (Relative Strength Index) on the daily chart of Deka Deutsche Boerse EUROGOV France UCI‚Ä¶ https://t.co/pTa4KWiS0a,nan,I found you an Oversold RSI (Relative Strength Index) on the daily chart of Deka Deutsche Boerse EUROGOV France UCI‚Ä¶ https://t.co/pTa4KWiS0a,neutral,0.03,0.89,0.08,neutral,0.03,0.89,0.08,True,English,"['Deka Deutsche Boerse EUROGOV France UCI', 'Relative Strength Index', 'Oversold RSI', 'daily chart', 'pTa4KWiS0a', 'Deka Deutsche Boerse EUROGOV France UCI', 'Relative Strength Index', 'Oversold RSI', 'daily chart', 'pTa4KWiS0a']",2022-06-05,2022-06-05,Unknown
6022,EuroNext,NewsApi.org,https://finance.yahoo.com/news/vgp-nv-upcoming-inclusion-ftse-050000684.html,VGP NV: Upcoming Inclusion in the FTSE EPRA Nareit Developed Europe Index,PRESS RELEASE Regulated Information 4 June 2022  07:00 CET  Antwerp  Belgium: VGP NV (‚ÄòVGP‚Äô or ‚Äòthe Group‚Äô)  a European provider of high-quality logistics...,VGP NVPRESS RELEASERegulated Information4 June 2022  07:00 CET  Antwerp  Belgium: VGP NV (‚ÄòVGP‚Äô or ‚Äòthe Group‚Äô)  a European provider of high-quality logistics and semi-industrial real estate  announced that its share has been admitted to the FTSE EPRA Nareit Developed Europe Index in the FTSE EPRA Nareit Global Real Estate Index Series (‚ÄúDeveloped Europe Index‚Äù). Its inclusion will be effective from the start of trading on Monday the 20th of June 2022.The admittance to the Developed Europe Index follows VGP‚Äôs inclusion in the FTSE EPRA Nareit Global Emerging Index on the 23rd of September 2019. The eligibility for the Developed Europe Index is dependent of a company‚Äôs market capitalization  the liquidity and free float of the share and the geographical location of the portfolio. In March of this year VGP was also included in Euronext Brussels‚Äô BEL20 Index.Dominique Moerenhout  EPRA CEO  said: ‚ÄúThe inclusion of VGP represents another solid step in the expansion of the Developed Europe Index with a truly Pan-European developer  owner and manager of logistics assets. VGP operates in 16 countries in a fast growing and innovative sector and following the admission to the BEL 20 earlier this year and their growing business activities in Western Europe the inclusion in the FTSE EPRA Nareit Developed Europe Index is timely. I would like to congratulate the VGP management team on reaching the next stage in their corporate development by being admitted to the leading benchmark alongside their successful market peers.‚ÄùJan Van Geet  CEO of VGP  said: ‚ÄúWe are very pleased to be included in EPRA‚Äôs Developed Europe Index. We are proud of our European roots and this is a recognition of the transformative progress VGP has made in recent years in becoming a pan-European platform that today serves over 400 clients and more than a 100 communities across the continent. The increased visibility in the capital markets through the index inclusion will further support our development as a business.‚ÄùStory continuesThe European Public Real Estate Association  registered in Belgium and founded in 1999  represents the publicly traded European real estate sector  with more than 280 members. EPRA represents over ‚Ç¨ 690 billion of real estate assets[1] and 94% of the market capitalisation of the FTSE EPRA Nareit Europe Index. Their mission is to promote  develop and represent the European public real estate sector.CONTACT DETAILS FOR INVESTORS AND MEDIA ENQUIRIESInvestor RelationsTel: +32 (0)3 289 1433investor.relations@vgpparks.eu Petra Vanclova(External Communications)| Tel: +42 0 602 262 107 Anette NachbarBrunswick Group Tel: +49 152 288 10363ABOUT VGPVGP is a pan-European developer  manager and owner of high-quality logistics and semi-industrial real estate. VGP operates a fully integrated business model with capabilities and longstanding expertise across the value chain. The company has a development land bank (owned or committed) of 10.94 million m¬≤ and the strategic focus is on the development of business parks. Founded in 1998 as a Belgian family-owned real estate developer in the Czech Republic  VGP with a staff of circa 350 employees today operates in 16 European countries directly and through several 50:50 joint ventures. As of December 2021  the Gross Asset Value of VGP  including the joint ventures at 100%  amounted to ‚Ç¨ 5.75 billion and the company had a Net Asset Value (EPRA NTA) of ‚Ç¨ 2.33 billion. VGP is listed on Euronext Brussels (ISIN: BE0003878957).For more information  please visit: http://www.vgpparks.euAttachment,neutral,0.01,0.97,0.02,positive,0.75,0.2,0.04,True,English,"['FTSE EPRA Nareit Developed Europe Index', 'VGP NV', 'Upcoming Inclusion', 'FTSE EPRA Nareit Global Real Estate Index Series', 'FTSE EPRA Nareit Global Emerging Index', 'The European Public Real Estate Association', 'FTSE EPRA Nareit Developed Europe Index', 'FTSE EPRA Nareit Europe Index', 'Belgian family-owned real estate developer', 'European public real estate sector', 'European real estate sector', 'PRESS RELEASE Regulated Information', 'Euronext Brussels‚Äô BEL20 Index', 'semi-industrial real estate', 'real estate assets', 'Jan Van Geet', 'Gross Asset Value', 'Net Asset Value', 'successful market peers', 'integrated business model', 'several 50:50 joint ventures', 'growing business activities', 'development land bank', 'VGP management team', 'EPRA NTA', 'Western Europe', 'innovative sector', 'EPRA CEO', 'index inclusion', 'European provider', 'Pan-European developer', 'European roots', '16 European countries', 'value chain', 'logistics assets', 'fast growing', 'market capitalization', 'market capitalisation', 'business parks', 'high-quality logistics', 'free float', 'geographical location', 'Dominique Moerenhout', 'solid step', 'next stage', 'leading benchmark', 'transformative progress', 'recent years', 'pan-European platform', 'capital markets', 'CONTACT DETAILS', 'MEDIA ENQUIRIES', 'Petra Vanclova', 'External Communications', 'Anette Nachbar', 'longstanding expertise', '10.94 million m¬≤', 'strategic focus', 'Czech Republic', 'corporate development', 'Brunswick Group', 'VGP NV', 'Investor Relations', '16 countries', 'June', 'Antwerp', 'Belgium', 'share', 'start', 'trading', 'Monday', '20th', 'admittance', '23rd', 'September', 'eligibility', 'company', 'liquidity', 'portfolio', 'March', 'expansion', 'owner', 'manager', 'admission', 'recognition', '400 clients', '100 communities', 'continent', 'visibility', 'Story', '280 members', 'INVESTORS', 'Tel', 'vgpparks', 'capabilities', 'staff', '350 employees', 'December', 'ISIN', 'Attachment', '07:00']",2022-06-04,2022-06-05,finance.yahoo.com
6023,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20220605005062/en/NANOBIOTIX-New-Data-Featuring-NBTXR3-Plus-Chemoradiation-and-in-the-Preoperative-Setting-Support-Broad-Applicability-for-Head-and-Neck-Cancer-and-Other-Solid-Tumor-Indications,NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications,PARIS & CAMBRIDGE  Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO ‚Äì‚Äì Nasdaq: NBTX ‚Äì the ‚Äò‚ÄòCompany‚Äô‚Äô)  a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with can‚Ä¶,"PARIS & CAMBRIDGE  Mass.--(BUSINESS WIRE)--Regulatory News:NANOBIOTIX (Euronext : NANO ‚Äì‚Äì Nasdaq: NBTX ‚Äì the ‚Äò‚ÄòCompany‚Äô‚Äô)  a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer  today announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO) featuring potential first-in-class radioenhancer NBTXR3 in combination with concurrent chemoradiation for the treatment of head and neck cancer and rectal cancer. Nanobiotix also presented a trial-in-progress poster on the study design of the Company's ongoing pivotal phase 3 study  NANORAY-312  evaluating NBTXR3 as a single agent activated by radiotherapy for the treatment of elderly and frail patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who are ineligible for platinum-based chemotherapy (cisplatin).In view of the Company's strategy for development of NBTXR3 as a product candidate that can integrate across solid tumor indications along with major treatment modalities within each indication  starting with head and neck cancer  the company believes these new data add support for the radioenhancer in combination with chemoradiation and as a neoadjuvant (preoperative) therapy with the potential to improve surgical outcomes. ""Revolutionizing treatment outcomes for millions of patients with cancer will require integration of NBTXR3 across solid tumor indications  treatment modalities  and lines of therapy where radiation is a part of the treatment regimen‚Äîstarting with head and neck cancer "" said Laurent Levy  co-founder and chairman of the executive board at Nanobiotix. ""Taken together with the clinical data we have already produced for NBTXR3 as a single agent activated by radiotherapy and as a combination agent with anti-PD-1  we view the new chemoradiation data presented at ASCO as critical validation of NBTXR3's feasibility across the standard of care. As we continue to prioritize our ongoing pivotal phase 3 study for elderly and frail patients with locally advanced head and neck squamous cell carcinoma  our aim is to build a comprehensive approach to the treatment of patients with locally advanced head and neck cancer that will serve as a model for our radioenhancer in other indications.""A Comprehensive Approach to Locally Advanced Head and Neck Cancer Inclusive of ChemoradiationMost cisplatin-eligible patients with LA-HNSCC receive multimodal therapy including high dose concurrent chemoradiation (CCRT) as the standard of care. While CCRT has shown to improve local control and extend survival  the toxicity of high dose cisplatin creates challenges. These challenges appear both in terms of compliance with the treatment regimen for patients undergoing therapy that can impair efficacy  and in terms of the patients' quality of life after treatment. Although changes to the treatment protocol have been explored in randomized studies to reduce toxicity and improve compliance  reduction in toxicity has also led to reduction in efficacy.These patients need innovative new therapeutic options that do not create additional burden in their administration  do not add combined toxicity to radiotherapy and chemotherapy  and have the potential to improve survival.A Phase 1b/2 Study Evaluating NBTXR3 in Combination with Concurrent Chemoradiation for Patients with Locally Advanced or Recurrent Head and Neck Squamous Cell CarcinomaThis study  sponsored  executed  and reported by former Nanobiotix collaborator in Asia  PharmaEngine  Inc. (PEI)  sought to evaluate the safety and feasibility of NBTXR3 intratumoral injection when added to low-dose weekly cisplatin-containing CCRT for patients with locally advanced or recurrent head and neck squamous cell carcinoma. The study also aimed to establish the recommended phase 2 dose (RP2D)  however the RP2D was not determined due to stoppage of the phase 1b part of the trial resulting from the conclusion of the collaboration between PEI and Nanobiotix in 2021.Adult patients with T3-4 LA-HNSCC suitable for cisplatin were eligible for the study and 12 such patients were enrolled. These patients received a single intratumoral injection of NBTXR3  followed by a low-dose weekly regimen of CCRT. All 12 patients were deemed evaluable and all had stage 4 locally advanced disease.Of these evaluable patients  3  6  and 3 patients received NBTXR3 at the 5%  10%  and 15% dose levels  respectively. No serious adverse events (SAEs) inconsistent with what would normally be expected from a low-dose CCRT regimen were observed. Dose-limiting toxicities of grade 3 increased ALT and grade 3 increased AST were observed in one patient at the 10% dose level. Common Grade 3 adverse events (AEs) observed across dose levels were stomatitis  decreased WBC  decreased appetite  decreased neutrophil count  and leukopenia. One patient experienced grade 4 hyponatremia.Preliminary efficacy results showed a disease control rate of 100%  with an overall response rate of 58.3% according to RECIST 1.1. The study concluded that adding a single intratumoral injection of NBTXR3 to weekly low dose cisplatin-containing CCRT was feasible and had a favorable safety profile for patients with LA-HNSCC.Strengthening Support for NBTXR3 in Combination with Chemoradiation in the Preoperative SettingColorectal cancer (CRC) is the third most common cancer indication worldwide and the second leading cause of cancer-related death in the United States. One-third of CRCs appear in the rectum. For patients with locally advanced rectal cancer (LARC)  combined modality therapy with neoadjuvant CCRT  followed by total mesorectal excision (TME; surgery)  followed by adjuvant (post-operative) systemic chemotherapy is the current standard of care. The aim of the neoadjuvant portion of the treatment regimen is to control and downstage the disease to allow for R0 TME (surgical removal with a negative margin in which no gross or microscopic tumor remains in the primary tumor bed)  as clinical studies have shown a positive correlation between improved cancer-specific survival and R0 TME. While outcomes have improved  patients are still faced with a highly toxic treatment regimen that can lead to a lack of compliance which may hamper efficacy  along with deteriorated quality of life after treatment.Innovation with the potential to improve the rate of R0 resection without adding toxicity is an urgent need for this patient population.A Phase 1b/2 Study Evaluating NBTXR3 in Combination with Concurrent Chemoradiation in the Neoadjuvant Setting for Patients with Locally Advanced or Unresectable Rectal CancerThis study  sponsored  executed  and presented by PEI  sought to evaluate safety  feasibility  and early signs of efficacy for neoadjuvant NBTXR3 combined with CCRT followed by surgery for patients with locally advanced or unresectable rectal cancer. The study established the recommended phase 2 dose of NBTXR3 at 22% of gross tumor volume  however the phase 2 part of the trial was stopped as a result of the conclusion of the collaboration between PEI and Nanobiotix in 2021. Adult and older patients with T3-T4 locally advanced or unresectable rectal cancer suitable for chemoradiation were eligible for the study and 32 such patients were enrolled. These patients received a single intratumoral injection of NBTXR3  followed by a weekly regimen of CCRT. 31 of 32 patients were deemed evaluable and none of the evaluable patients had tumors eligible for surgery at the time of diagnosis.Of the 31 evaluable patients  6  4  3  and 18 patients received NBTXR3 at the 5%  10%  15%  and 22% dose levels  respectively. No NBTXR3-related SAEs or grade ‚â• 3 AEs were observed. The most frequently reported AEs were grade 1 or 2 decreased WBC  diarrhea  increased CRP  UTI  and decreased lymphocyte count which were all consistent with what would normally be expected from CCRT.Preliminary efficacy results showed a disease control rate of 100%  with an overall response rate of 35.5% according to RECIST 1.1. Pathological tumor downstaging was observed in 14 of 31 patients after therapy  25 patients underwent surgery  and 96% of those patients achieved R0 surgical margins. Pathological complete response was observed in 20% of the patients who received surgery. The study concluded that a single intratumoral injection of NBTXR3 in combination with CCRT is feasible and has a favorable safety profile in the neoadjuvant setting for patients with locally advanced or unresectable rectal adenocarcinoma.***About NBTXR3NBTXR3 is a novel  potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate‚Äôs physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy  subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA  Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination  particularly immune checkpoint inhibitors.About NANOBIOTIXNanobiotix is a late-stage clinical biotechnology company pioneering disruptive  physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform  including its lead product candidate  radiotherapy activated NBTXR3  to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.For more information about Nanobiotix  visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.DisclaimerThis press release contains certain ‚Äúforward-looking‚Äù statements within the meaning of applicable securities laws  including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as ‚Äúat this time ‚Äù ‚Äúanticipate ‚Äù ‚Äúbelieve ‚Äù ‚Äúexpect ‚Äù ‚Äúintend ‚Äù ‚Äúon track ‚Äù ‚Äúplan ‚Äù ‚Äúscheduled ‚Äù and ‚Äúwill ‚Äù or the negative of these and similar expressions. These forward-looking statements  which are based on our management‚Äôs current expectations and assumptions and on information currently available to management  include statements about the timing and progress of clinical trials  the timing of our presentation of data  the results of our preclinical and clinical studies and their potential implications. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However  these forward-looking statements are subject to numerous risks and uncertainties  including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive early clinical results and the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore  many other important factors  including those described in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 8  2022 under ‚ÄúItem 3.D. Risk Factors‚Äù and those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorit√© des March√©s Financiers ‚Äì the AMF) on April 8  2022  each as updated in our Half-Year Financial Report filed with the AMF and the SEC on September 8  2021 (a copy of which is available on www.nanobiotix.com)  as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results  performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law  we assume no obligation to update these forward-looking statements publicly  or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements  even if new information becomes available in the future.",neutral,0.04,0.94,0.02,mixed,0.07,0.19,0.74,True,English,"['Other Solid Tumor Indications', 'NBTXR3 Plus Chemoradiation', 'New Data', 'Preoperative Setting', 'Broad Applicability', 'Neck Cancer', 'NANOBIOTIX', 'Head', 'neck squamous cell carcinoma', 'innovative new therapeutic options', 'ongoing pivotal phase 3 study', 'A Phase 1b/2 Study', 'Common Grade 3 adverse events', 'low-dose weekly cisplatin-containing CCRT', 'late-clinical stage biotechnology company', 'high dose concurrent chemoradiation', 'serious adverse events', 'low-dose weekly regimen', 'overall response rate', 'solid tumor indications', 'phase 1b part', 'single intratumoral injection', 'low-dose CCRT regimen', 'high dose cisplatin', 'Preliminary efficacy results', 'disease control rate', 'NBTXR3 intratumoral injection', 'Most cisplatin-eligible patients', 'former Nanobiotix collaborator', 'major treatment modalities', 'new chemoradiation data', 'class radioenhancer NBTXR3', 'phase 2 dose', 'new data', 'other indications', 'neck cancer', 'local control', '15% dose levels', '10% dose level', 'study design', 'single agent', 'clinical data', 'treatment regimen', 'BUSINESS WIRE', 'Regulatory News', 'physics-based approaches', '2022 Annual Meeting', 'American Society', 'Clinical Oncology', 'progress poster', 'product candidate', 'surgical outcomes', 'Laurent Levy', 'executive board', 'critical validation', 'comprehensive approach', 'randomized studies', 'additional burden', 'Dose-limiting toxicities', 'one patient', 'neutrophil count', 'grade 4 hyponatremia', 'rectal cancer', 'treatment possibilities', 'treatment outcomes', 'treatment protocol', 'Recurrent Head', 'platinum-based chemotherapy', 'preoperative) therapy', 'multimodal therapy', 'frail patients', ""patients' quality"", 'Adult patients', 'evaluable patients', 'T3-4 LA-HNSCC', 'advanced head', 'combination agent', 'combined toxicity', 'stage 4', '12 patients', '3 patients', 'PARIS', 'CAMBRIDGE', 'Mass', 'Euronext', 'Nasdaq', 'reporting', 'ASCO', 'potential', 'trial', 'NANORAY', 'radiotherapy', 'elderly', 'view', 'strategy', 'development', 'support', 'neoadjuvant', 'Revolutionizing', 'millions', 'integration', 'lines', 'founder', 'chairman', 'anti-PD-1', 'feasibility', 'standard', 'care', 'aim', 'model', 'survival', 'challenges', 'terms', 'compliance', 'life', 'changes', 'reduction', 'administration', 'Asia', 'PharmaEngine', 'Inc.', 'PEI', 'safety', 'RP2D', 'stoppage', 'conclusion', 'collaboration', 'SAEs', 'ALT', 'AST', 'stomatitis', 'WBC', 'appetite', 'leukopenia', 'RECIST']",2022-06-05,2022-06-05,businesswire.com
6024,EuroNext,Google API,http://www.businesswire.com/news/home/20220605005022/en/NOXXON-Presents-Full-Top-line-Results-From-NOX-A12-Phase-12-GLORIA-Trial-in-Glioblastoma-at-the-2022-ASCO-Annual-Meeting,NOXXON Presents Full Top-line Results From NOX-A12 Phase 1/2 GLORIA Trial in Glioblastoma at the 2022 ASCO Annual Meeting,8 hours ago,"BERLIN--(BUSINESS WIRE)--Regulatory News:NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX)  a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME)  announced today the publication of the full top-line results from the NOX-A12 Phase 1/2 GLORIA trial in brain cancer (glioblastoma) in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting  taking place in Chicago  Illinois  US  from June 3 to June 7  2022.The poster presentation entitled ‚ÄúRadiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial‚Äù was presented by Dr. Frank A. Giordano and highlighted that:90% of patients who received NOX-A12 and radiotherapy achieved tumor size reductions vs. 25% of patients in a matched reference cohort receiving standard of care.40% of patients who received NOX-A12 and radiotherapy achieved partial response (defined as tumor size reduction of more than 50%) vs. 10% in a matched reference cohort receiving standard of care.In 30% of patients who received NOX-A12 and radiotherapy  one or more non-target lesions (smaller secondary lesions) completely disappeared.Infiltration of the tumor with activated  cytotoxic T-cells and M1-like macrophages was seen in both patients who had repeat surgery during NOX-A12 therapy  consistent with NOX-A12 and radiotherapy overcoming immune cell exclusion and making the tumors immunologically hotter.The combination of NOX-A12 and radiotherapy was safe and well tolerated  with no dose limiting toxicities and no treatment-related deaths. Only 4% of the adverse events of Grade 2 or more were deemed solely NOX-A12-related.Aram Mangasarian  CEO of NOXXON  commented: ""We are excited about these impressive results  which demonstrate the potential of our lead asset NOX-A12 in brain cancer and further substantiate our innovative approach of targeting the tumor microenvironment. We will continue to report on maturing data from the dose-escalation part of the study and are looking forward to interim read-outs from the ongoing expansion study exploring additional combination therapies  which will help us design our planned pivotal trial. Brain cancer is a very difficult to treat condition and these results bring us a step closer to offering improved treatment options and hope for patients.""Dr. Frank A. Giordano  Director and Chair of the Department of Radiation Oncology at the University Hospital Bonn and the lead investigator of the GLORIA trial  commented: ""These encouraging results show a strong response to NOX-A12 and radiotherapy  with 90% of patients achieving tumor size reduction. In addition to this  the 40% of patients who have achieved more than 50% tumor size reduction under NOX‚ÄëA12 treatment is a considerable increase over the 22% disclosed in the previous interim data analysis  and a multi-fold increase over the 10% achieved by the reference cohort receiving standard of care. This suggests the promising clinical efficacy of this new approach to directly target CXCL12 in glioblastoma.""A copy of the poster presentation and a video describing the poster  is available on the NOXXON website. More information about the GLORIA study (NCT04121455) can be found at ClinicalTrials.gov.Following the ASCO 2022 conference  NOXXON will host a Key Opinion Leader (KOL) webinar with Dr. Giordano  who will take the audience through the ASCO poster presentation and discuss the results of the GLORIA Phase 1/2 trial in more detail.Details of the Key Opinion Leader webinar are as follows:Title: KOL Webinar on GLORIA Top-Line Results of NOX-A12 & Radiotherapy Combination in First-Line Glioblastoma Presented at ASCO 2022Presenter: Dr. Frank A. Giordano  Director and Chair of the Department of Radiation Oncology  University Hospital Bonn  GermanyWebinar time and date: June 10  2022  at 02:00 p.m. CEST (08:00 a.m. EDT)Registration: To register for the event  please click hereAbout NOXXONNOXXON‚Äôs oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME  NOXXON‚Äôs approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON‚Äôs lead program NOX-A12 has delivered final top-line data from a Keytruda¬Æ combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study  OPTIMUS  to further evaluate safety and efficacy of NOX-A12 in combination with Merck‚Äôs Keytruda¬Æ and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA  a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered top-line data from all three dose-escalation cohorts showing consistent tumor reductions and objective tumor responses. Additionally  GLORIA has been expanded to assess the benefit of NOX-A12 with other treatment combinations  radiotherapy + bevacizumab and radiotherapy + pembrolizumab. The company‚Äôs second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX‚ÄëE36 in patients with solid tumors. Further information can be found at: www.noxxon.com.Keytruda¬Æ is a registered trademark of Merck Sharp & Dohme Corp.Visit NOXXON on LinkedIn and Twitter.About the GLORIA StudyGLORIA (NCT04121455) is NOXXON‚Äôs dose-escalation  phase 1/2 study of NOX-A12 in combination with irradiation in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.About the OPTIMUS StudyOPTIMUS (NCT04901741) is NOXXON‚Äôs open-label two-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.DisclaimerTranslations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English  but due to the nuances in translating into another language  slight differences may exist. Certain statements in this communication contain formulations or terms referring to the future or future developments  as well as negations of such formulations or terms  or similar terminology. These are described as forward-looking statements. In addition  all information in this communication regarding planned or future results of business segments  financial indicators  developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information  which only represents the state of affairs on the day of publication.",neutral,0.01,0.97,0.01,mixed,0.47,0.18,0.35,True,English,"['NOX-A12 Phase 1/2 GLORIA Trial', 'Full Top-line Results', '2022 ASCO Annual Meeting', 'NOXXON', 'Glioblastoma', 'German multicenter phase 1/2 GLORIA trial', 'NOX-A12 Phase 1/2 GLORIA trial', 'GLORIA Phase 1/2 trial', 'two different chemotherapy regimens', 'Dr. Frank A. Giordano', 'NOXXON Pharma N.V.', 'previous interim data analysis', 'Key Opinion Leader webinar', 'University Hospital Bonn', 'greater therapeutic impact', 'orphan drug status', 'final top-line data', 'GLORIA Top-Line Results', 'smaller secondary lesions', 'immune cell exclusion', 'cancer immunity cycle', 'tumor size reductions', '50% tumor size reduction', 'tumor protection barrier', 'ASCO) Annual Meeting', 'Euronext Growth Paris', 'full top-line results', 'ongoing expansion study', 'improved treatment options', 'NOX‚ÄëA12 treatment', 'metastatic pancreatic cancer', 'additional combination therapies', 'promising clinical efficacy', 'Keytruda¬Æ combination trial', 'Dr. Giordano', 'pancreatic cancer patients', 'ASCO poster presentation', 'Phase 2 study', 'pivotal trial', 'GLORIA study', 'maturing data', 'interim read-outs', 'Clinical Oncology', 'non-target lesions', 'KOL) webinar', 'KOL Webinar', 'Webinar time', 'immune system', 'metastatic colorectal', 'cancer treatments', 'brain cancer', 'tumor microenvironment', 'tumor repair', 'tumor defenses', 'ASCO 2022 conference', 'BUSINESS WIRE', 'Regulatory News', '2022 American Society', 'olaptesed pegol', 'reference cohort', 'partial response', 'cytotoxic T-cells', 'M1-like macrophages', 'limiting toxicities', 'treatment-related deaths', 'adverse events', 'Aram Mangasarian', 'impressive results', 'lead asset', 'dose-escalation part', 'Radiation Oncology', 'lead investigator', 'encouraging results', 'strong response', 'considerable increase', 'multi-fold increase', 'More information', 'ClinicalTrials.gov', 'oncology-focused pipeline', 'other forms', 'lead program', 'ESMO conference', 'second-line therapy', 'innovative approach', 'new approach', 'biotechnology company', 'MGMT-unmethylated glioblastoma', 'First-Line Glioblastoma', 'NOXXON website', 'NOX-A12 therapy', 'Radiotherapy Combination', 'BERLIN', 'ALNOX', 'publication', 'place', 'Chicago', 'Illinois', 'June', 'standard', 'care', 'Infiltration', 'surgery', 'tumors', 'Grade', 'CEO', 'potential', 'condition', 'hope', 'Director', 'Chair', 'Department', 'CXCL12', 'copy', 'video', 'audience', 'detail', 'Title', 'Presenter', 'Germany', 'date', 'CEST', 'Registration', 'chemokines', 'September', 'July', 'OPTIMUS', 'safety', 'Merck', '02:00']",2022-06-05,2022-06-05,businesswire.com
6025,EuroNext,Google API,https://www.pharmiweb.com/press-release/2022-06-05/nanobiotix-new-data-featuring-nbtxr3-plus-chemoradiation-and-in-the-preoperative-setting-support-br,NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications,4 hours ago,"Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology  and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination with chemoradiation and in the preoperative settingData from the phase 1b/2 head and neck cancer study in 12 evaluable patients with stage 4 disease showed that combining NBTXR3 with concurrent chemoradiation was feasible  had a favorable safety profile  produced a 100% disease control rate  and an overall response rate of 58.3%Data from the phase 1b/2 rectal cancer study in 31 evaluable patients with unresectable disease showed that combining NBTXR3 with concurrent chemoradiation in the preoperative setting was feasible  had a favorable safety profile  enabled 96% of evaluable patients to undergo R0 surgery  produced a 100% disease-control rate  a 35.5% overall response rate  and a 20% pathological complete response rate in 25 patients who underwent surgeryPARIS & CAMBRIDGE  Mass.--(BUSINESS WIRE)--Regulatory News:NANOBIOTIX (Euronext : NANO ‚Äì‚Äì Nasdaq: NBTX ‚Äì the ‚Äò‚ÄòCompany‚Äô‚Äô)  a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer  today announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO) featuring potential first-in-class radioenhancer NBTXR3 in combination with concurrent chemoradiation for the treatment of head and neck cancer and rectal cancer. Nanobiotix also presented a trial-in-progress poster on the study design of the Company's ongoing pivotal phase 3 study  NANORAY-312  evaluating NBTXR3 as a single agent activated by radiotherapy for the treatment of elderly and frail patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who are ineligible for platinum-based chemotherapy (cisplatin).In view of the Company's strategy for development of NBTXR3 as a product candidate that can integrate across solid tumor indications along with major treatment modalities within each indication  starting with head and neck cancer  the company believes these new data add support for the radioenhancer in combination with chemoradiation and as a neoadjuvant (preoperative) therapy with the potential to improve surgical outcomes. ""Revolutionizing treatment outcomes for millions of patients with cancer will require integration of NBTXR3 across solid tumor indications  treatment modalities  and lines of therapy where radiation is a part of the treatment regimen‚Äîstarting with head and neck cancer "" said Laurent Levy  co-founder and chairman of the executive board at Nanobiotix. ""Taken together with the clinical data we have already produced for NBTXR3 as a single agent activated by radiotherapy and as a combination agent with anti-PD-1  we view the new chemoradiation data presented at ASCO as critical validation of NBTXR3's feasibility across the standard of care. As we continue to prioritize our ongoing pivotal phase 3 study for elderly and frail patients with locally advanced head and neck squamous cell carcinoma  our aim is to build a comprehensive approach to the treatment of patients with locally advanced head and neck cancer that will serve as a model for our radioenhancer in other indications.""A Comprehensive Approach to Locally Advanced Head and Neck Cancer Inclusive of ChemoradiationMost cisplatin-eligible patients with LA-HNSCC receive multimodal therapy including high dose concurrent chemoradiation (CCRT) as the standard of care. While CCRT has shown to improve local control and extend survival  the toxicity of high dose cisplatin creates challenges. These challenges appear both in terms of compliance with the treatment regimen for patients undergoing therapy that can impair efficacy  and in terms of the patients' quality of life after treatment. Although changes to the treatment protocol have been explored in randomized studies to reduce toxicity and improve compliance  reduction in toxicity has also led to reduction in efficacy.These patients need innovative new therapeutic options that do not create additional burden in their administration  do not add combined toxicity to radiotherapy and chemotherapy  and have the potential to improve survival.A Phase 1b/2 Study Evaluating NBTXR3 in Combination with Concurrent Chemoradiation for Patients with Locally Advanced or Recurrent Head and Neck Squamous Cell CarcinomaThis study  sponsored  executed  and reported by former Nanobiotix collaborator in Asia  PharmaEngine  Inc. (PEI)  sought to evaluate the safety and feasibility of NBTXR3 intratumoral injection when added to low-dose weekly cisplatin-containing CCRT for patients with locally advanced or recurrent head and neck squamous cell carcinoma. The study also aimed to establish the recommended phase 2 dose (RP2D)  however the RP2D was not determined due to stoppage of the phase 1b part of the trial resulting from the conclusion of the collaboration between PEI and Nanobiotix in 2021.Adult patients with T3-4 LA-HNSCC suitable for cisplatin were eligible for the study and 12 such patients were enrolled. These patients received a single intratumoral injection of NBTXR3  followed by a low-dose weekly regimen of CCRT. All 12 patients were deemed evaluable and all had stage 4 locally advanced disease.Of these evaluable patients  3  6  and 3 patients received NBTXR3 at the 5%  10%  and 15% dose levels  respectively. No serious adverse events (SAEs) inconsistent with what would normally be expected from a low-dose CCRT regimen were observed. Dose-limiting toxicities of grade 3 increased ALT and grade 3 increased AST were observed in one patient at the 10% dose level. Common Grade 3 adverse events (AEs) observed across dose levels were stomatitis  decreased WBC  decreased appetite  decreased neutrophil count  and leukopenia. One patient experienced grade 4 hyponatremia.Preliminary efficacy results showed a disease control rate of 100%  with an overall response rate of 58.3% according to RECIST 1.1. The study concluded that adding a single intratumoral injection of NBTXR3 to weekly low dose cisplatin-containing CCRT was feasible and had a favorable safety profile for patients with LA-HNSCC.Strengthening Support for NBTXR3 in Combination with Chemoradiation in the Preoperative SettingColorectal cancer (CRC) is the third most common cancer indication worldwide and the second leading cause of cancer-related death in the United States. One-third of CRCs appear in the rectum. For patients with locally advanced rectal cancer (LARC)  combined modality therapy with neoadjuvant CCRT  followed by total mesorectal excision (TME; surgery)  followed by adjuvant (post-operative) systemic chemotherapy is the current standard of care. The aim of the neoadjuvant portion of the treatment regimen is to control and downstage the disease to allow for R0 TME (surgical removal with a negative margin in which no gross or microscopic tumor remains in the primary tumor bed)  as clinical studies have shown a positive correlation between improved cancer-specific survival and R0 TME. While outcomes have improved  patients are still faced with a highly toxic treatment regimen that can lead to a lack of compliance which may hamper efficacy  along with deteriorated quality of life after treatment.Innovation with the potential to improve the rate of R0 resection without adding toxicity is an urgent need for this patient population.A Phase 1b/2 Study Evaluating NBTXR3 in Combination with Concurrent Chemoradiation in the Neoadjuvant Setting for Patients with Locally Advanced or Unresectable Rectal CancerThis study  sponsored  executed  and presented by PEI  sought to evaluate safety  feasibility  and early signs of efficacy for neoadjuvant NBTXR3 combined with CCRT followed by surgery for patients with locally advanced or unresectable rectal cancer. The study established the recommended phase 2 dose of NBTXR3 at 22% of gross tumor volume  however the phase 2 part of the trial was stopped as a result of the conclusion of the collaboration between PEI and Nanobiotix in 2021. Adult and older patients with T3-T4 locally advanced or unresectable rectal cancer suitable for chemoradiation were eligible for the study and 32 such patients were enrolled. These patients received a single intratumoral injection of NBTXR3  followed by a weekly regimen of CCRT. 31 of 32 patients were deemed evaluable and none of the evaluable patients had tumors eligible for surgery at the time of diagnosis.Of the 31 evaluable patients  6  4  3  and 18 patients received NBTXR3 at the 5%  10%  15%  and 22% dose levels  respectively. No NBTXR3-related SAEs or grade ‚â• 3 AEs were observed. The most frequently reported AEs were grade 1 or 2 decreased WBC  diarrhea  increased CRP  UTI  and decreased lymphocyte count which were all consistent with what would normally be expected from CCRT.Preliminary efficacy results showed a disease control rate of 100%  with an overall response rate of 35.5% according to RECIST 1.1. Pathological tumor downstaging was observed in 14 of 31 patients after therapy  25 patients underwent surgery  and 96% of those patients achieved R0 surgical margins. Pathological complete response was observed in 20% of the patients who received surgery. The study concluded that a single intratumoral injection of NBTXR3 in combination with CCRT is feasible and has a favorable safety profile in the neoadjuvant setting for patients with locally advanced or unresectable rectal adenocarcinoma.***About NBTXR3NBTXR3 is a novel  potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate‚Äôs physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy  subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA  Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination  particularly immune checkpoint inhibitors.About NANOBIOTIXNanobiotix is a late-stage clinical biotechnology company pioneering disruptive  physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform  including its lead product candidate  radiotherapy activated NBTXR3  to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.For more information about Nanobiotix  visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.DisclaimerThis press release contains certain ‚Äúforward-looking‚Äù statements within the meaning of applicable securities laws  including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as ‚Äúat this time ‚Äù ‚Äúanticipate ‚Äù ‚Äúbelieve ‚Äù ‚Äúexpect ‚Äù ‚Äúintend ‚Äù ‚Äúon track ‚Äù ‚Äúplan ‚Äù ‚Äúscheduled ‚Äù and ‚Äúwill ‚Äù or the negative of these and similar expressions. These forward-looking statements  which are based on our management‚Äôs current expectations and assumptions and on information currently available to management  include statements about the timing and progress of clinical trials  the timing of our presentation of data  the results of our preclinical and clinical studies and their potential implications. Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable. However  these forward-looking statements are subject to numerous risks and uncertainties  including with respect to the risk that subsequent studies and ongoing or future clinical trials may not generate favorable data notwithstanding positive early clinical results and the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to it. Furthermore  many other important factors  including those described in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on April 8  2022 under ‚ÄúItem 3.D. Risk Factors‚Äù and those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorit√© des March√©s Financiers ‚Äì the AMF) on April 8  2022  each as updated in our Half-Year Financial Report filed with the AMF and the SEC on September 8  2021 (a copy of which is available on www.nanobiotix.com)  as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results  performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law  we assume no obligation to update these forward-looking statements publicly  or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements  even if new information becomes available in the future.NanobiotixCommunications DepartmentBrandon OwensVP  Communications+1 (617) 852-4835contact@nanobiotix.comInvestor Relations DepartmentKate McNeilSVP  Investor Relations+1 (609) 678-7388investors@nanobiotix.comMedia RelationsFR ‚Äì Ulysse CommunicationPierre-Louis Germain+ 33 (0) 6 64 79 97 51plgermain@ulysse-communication.comUS ‚Äì Porter NovelliCaitlin Hunt+1 (781) 985-5967Caitlin.hunt@porternovelli.com",neutral,0.04,0.94,0.02,mixed,0.12,0.19,0.69,True,English,"['Other Solid Tumor Indications', 'NBTXR3 Plus Chemoradiation', 'New Data', 'Preoperative Setting', 'Broad Applicability', 'Neck Cancer', 'NANOBIOTIX', 'Head', 'phase 1b/2 rectal cancer study', 'neck squamous cell carcinoma', 'innovative new therapeutic options', 'collaborator-sponsored phase 1b/2 studies', 'ongoing pivotal phase 3 study', 'A Phase 1b/2 Study', '20% pathological complete response rate', 'low-dose weekly cisplatin-containing CCRT', 'late-clinical stage biotechnology company', 'high dose concurrent chemoradiation', 'overall response rate', 'phase 1b/2 head', 'solid tumor indications', 'phase 1b part', 'high dose cisplatin', 'favorable safety profile', 'neck cancer study', '100% disease control rate', 'Most cisplatin-eligible patients', 'former Nanobiotix collaborator', 'NBTXR3 intratumoral injection', 'major treatment modalities', 'phase 2 dose', 'new chemoradiation data', 'class radioenhancer NBTXR3', 'stage 4 disease', '100% disease-control rate', 'study design', 'randomized studies', 'other indications', 'local control', 'new data', 'unresectable disease', '2022 Annual Meeting', 'American Society', 'product candidate', 'preoperative setting', 'BUSINESS WIRE', 'Regulatory News', 'physics-based approaches', 'progress poster', 'single agent', 'surgical outcomes', 'Laurent Levy', 'executive board', 'critical validation', 'comprehensive approach', 'additional burden', 'treatment possibilities', 'treatment outcomes', 'treatment regimen', 'treatment protocol', 'Recurrent Head', 'Clinical Oncology', 'clinical data', '12 evaluable patients', '31 evaluable patients', 'frail patients', ""patients' quality"", 'R0 surgery', 'platinum-based chemotherapy', 'preoperative) therapy', 'multimodal therapy', 'advanced head', 'combined toxicity', 'combination agent', '25 patients', 'potential', 'standards', 'care', 'support', 'PARIS', 'CAMBRIDGE', 'Mass', 'Euronext', 'Nasdaq', 'reporting', 'ASCO', 'trial', 'NANORAY', 'radiotherapy', 'elderly', 'LA-HNSCC', 'view', 'strategy', 'development', 'neoadjuvant', 'Revolutionizing', 'millions', 'integration', 'lines', 'founder', 'chairman', 'anti-PD-1', 'feasibility', 'aim', 'model', 'survival', 'challenges', 'terms', 'compliance', 'efficacy', 'life', 'changes', 'reduction', 'administration', 'Asia', 'PharmaEngine', 'Inc.', 'PEI', 'RP2D', 'stoppage', 'conclusion']",2022-06-05,2022-06-05,pharmiweb.com
6026,EuroNext,Google API,https://www.directorstalkinterviews.com/public-storage---consensus-indicates-potential-16.5-upside/4121067081,Public Storage - Consensus Indicates Potential 16.5% Upside,7 hours ago,Public Storage found using ticker (PSA) now have 12 analysts covering the stock. The analyst consensus points to a rating of ‚ÄòBuy‚Äô. The target price ranges between 482 and 298 with the average target price sitting at 388. Given that the stocks previous close was at 332.92 this indicates there is a potential upside of 16.5%. There is a 50 day moving average of 364.33 and the 200 day MA is 346.4. The company has a market capitalisation of $58 212m. You can visit the company‚Äôs website by visiting: https://www.publicstorage.comThe potential market cap would be $67 843m based on the market concensus.You can now share this on Stocktwits  just click the logo below and add the ticker in the text to be seen.Public Storage  a member of the S&P 500 and FT Global 500  is a REIT that primarily acquires  develops  owns and operates self-storage facilities. At September 30  2020  we had: (i) interests in 2 504 self-storage facilities located in 38 states with approximately 171 million net rentable square feet in the United States  (ii) an approximate 35% common equity interest in Shurgard Self Storage SA (Euronext Brussels:SHUR) which owned 239 self-storage facilities located in seven Western European nations with approximately 13 million net rentable square feet operated under the ¬ìShurgard¬î brand and (iii) an approximate 42% common equity interest in PS Business Parks (NYSE:PSB) which owned and operated approximately 28 million rentable square feet of commercial space at September 30  2020. Our headquarters are located in Glendale  California.,neutral,0.05,0.89,0.06,neutral,0.01,0.96,0.03,True,English,"['Public Storage', 'Consensus', 'Potential', '171 million net rentable square feet', '28 million rentable square feet', 'approximate 35% common equity interest', 'seven Western European nations', 'approximate 42% common equity interest', 'Shurgard Self Storage SA', 'PS Business Parks', 'average target price', '50 day moving average', 'potential market cap', 'Shurgard brand', 'Public Storage', 'potential upside', 'market capitalisation', 'market concensus', 'S&P 500', 'FT Global 500', 'self-storage facilities', 'Euronext Brussels', 'commercial space', 'United States', '13 million', '200 day', '38 states', 'ticker', 'PSA', '12 analysts', 'stock', 'consensus', 'rating', 'Buy', 'company', 'website', 'publicstorage', 'logo', 'text', 'member', 'REIT', 'September', 'interests', 'NYSE', 'PSB', 'headquarters', 'Glendale', 'California']",2022-06-05,2022-06-05,directorstalkinterviews.com
6027,EuroNext,Google API,https://dbtnews.com/2022/06/04/jefferies-lifts-frontline-ltd-fro-price-estimate-who-else-is-bullish/,Jefferies lifts Frontline Ltd. [FRO] price estimate. Who else is bullish?,21 hours ago,Frontline Ltd. [NYSE: FRO] gained 0.69% or 0.07 points to close at $10.19 with a heavy trading volume of 3720420 shares. The company report on May 28  2022 that FRO ‚Äì Private acquisitions of Euronav shares in exchange for Frontline shares completed.3 Tiny Stocks Primed to Explode The world's greatest investor ‚Äî Warren Buffett ‚Äî has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.Click here for full details and to join for free. SponsoredFRO ‚Äì Private acquisitions of Euronav shares in exchange for Frontline shares completed .Frontline Ltd. (‚ÄúFrontline‚Äù or the ‚ÄúCompany‚Äù) (NYSE: FRO ‚Äì OSE: FRO) announces that it has agreed to acquire a total of 5 955 705 shares in Euronav N.V. (NYSE: EURN & Euronext: EURN) (‚ÄúEuronav‚Äù) representing 2.95% of the outstanding shares in privately negotiated share exchange transactions with certain shareholders of Euronav N.V. where such shareholders of Euronav N.V. receive consideration shares in Frontline.It opened the trading session at $10.38  the shares rose to $10.57 and dropped to $10.075  the range by which the price of stock traded the whole day. The daily chart for FRO points out that the company has recorded 58.97% gains over the past six months. However  it is still -67.05% lower than its most recent low trading price.If we look at the average trading volume of 2.88M shares  FRO reached to a volume of 3720420 in the most recent trading day  which is why market watchdogs consider the stock to be active.Here is what top equities market gurus are saying about Frontline Ltd. [FRO]:Jefferies have made an estimate for Frontline Ltd. shares  keeping their opinion on the stock as Hold  with their previous recommendation back on April 27  2022. The new note on the price target was released on May 25  2021  representing the official price target for Frontline Ltd. stock. Previously  the target price had yet another raise to $8  while H.C. Wainwright analysts kept a Neutral rating on FRO stock.The Average True Range (ATR) for Frontline Ltd. is set at 0.60  with the Price to Sales ratio for FRO stock in the period of the last 12 months amounting to 2.39. The Price to Book ratio for the last quarter was 1.23  with the Price to Cash per share for the same quarter was set at 0.63.Trading performance analysis for FRO stockFrontline Ltd. [FRO] fell into the red zone at the end of the last week  falling into a negative trend and dropping by -2.95. With this latest performance  FRO shares gained by 20.59% in over the last four-week period  additionally plugging by 58.97% over the last 6 months ‚Äì not to mention a rise of 20.88% in the past year of trading.Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI)  where an RSI result of over 70 would be overbought  and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FRO stock in for the last two-week period is set at 58.29  with the RSI for the last a single of trading hit 58.48  and the three-weeks RSI is set at 57.49 for Frontline Ltd. [FRO]. The present Moving Average for the last 50 days of trading for this stock 8.92  while it was recorded at 10.45 for the last single week of trading  and 8.16 for the last 200 days.Frontline Ltd. [FRO]: A deeper dive into fundamental analysisOperating Margin for any stock indicates how profitable investing would be  and Frontline Ltd. [FRO] shares currently have an operating margin of +18.77 and a Gross Margin at +21.47. Frontline Ltd.‚Äôs Net Margin is presently recorded at +30.70.Return on Total Capital for FRO is now 4.33  given the latest momentum  and Return on Invested Capital for the company is 4.52. Return on Equity for this stock inclined to 7.41  with Return on Assets sitting at 3.69. When it comes to the capital structure of this company  Frontline Ltd. [FRO] has a Total Debt to Total Equity ratio set at 83.23. Additionally  FRO Total Debt to Total Capital is recorded at 45.42  with Total Debt to Total Assets ending up at 35.22. Long-Term Debt to Equity for the company is recorded at 77.60  with the Long-Term Debt to Total Capital now at 42.35.Frontline Ltd.‚Äôs liquidity data is similarly interesting compelling  with a Current Ratio set at 0.70.An analysis of insider ownership at Frontline Ltd. [FRO]There are presently around $361 million  or 21.10% of FRO stock  in the hands of institutional investors. The top three institutional holders of FRO stocks are: BLACKROCK INC. with ownership of 6 310 581  which is approximately -0.241% of the company‚Äôs market cap and around 33.80% of the total institutional ownership; VANGUARD GROUP INC  holding 4 457 223 shares of the stock with an approximate value of $45.11 million in FRO stocks shares; and MARSHALL WACE  LLP  currently with $22.75 million in FRO stock with ownership of nearly New of the company‚Äôs market capitalization.Positions in Frontline Ltd. stocks held by institutional investors increased at the end of May and at the time of the May reporting period  where 63 institutional holders increased their position in Frontline Ltd. [NYSE:FRO] by around 10 448 032 shares. Additionally  62 investors decreased positions by around 14 910 676 shares  while 21 investors held positions by with 10 342 800 shares. The mentioned changes placed institutional holdings at 35 701 508 shares  according to the latest SEC report filing. FRO stock had 32 new institutional investments in for a total of 6 128 272 shares  while 18 institutional investors sold positions of 1 540 323 shares during the same period.,negative,0.01,0.12,0.87,mixed,0.18,0.16,0.67,True,English,"['Frontline Ltd.', 'Jefferies', 'H.C. Wainwright analysts', 'top three institutional holders', 'top equities market gurus', 'cheap small cap stocks', 'recent low trading price', 'huge upside potential', 'Relative Strength Index', 'present Moving Average', 'recent trading day', 'VANGUARD GROUP INC', 'last a single', 'Euronav N.V.', 'Average True Range', 'last single week', 'past six months', 'neutral market momentum', 'last four-week period', 'last two-week period', 'heavy trading volume', 'average trading volume', 'official price target', 'total institutional ownership', 'stock market investors', 'Trading performance analysis', 'share exchange transactions', 'Total Equity ratio', 'FRO stocks shares', 'Frontline Ltd. shares', 'FRO Total Debt', 'market cap', 'Frontline Ltd. stock', 'institutional investors', 'last week', 'market watchdogs', 'last 12 months', 'last 6 months', '3 Tiny Stocks', 'oversold stocks', 'Neutral rating', 'latest performance', 'past year', 'latest momentum', 'BLACKROCK INC.', 'last quarter', 'last 50 days', 'last 200 days', 'smart investors', 'Sales ratio', 'Book ratio', 'Current Ratio', 'target price', 'trading session', 'Total Capital', 'Long-Term Debt', 'Euronav shares', 'Private acquisitions', 'greatest investor', 'Warren Buffett', 'simple formula', 'big money', 'alert service', 'full advantage', 'big returns', 'full details', 'daily chart', 'previous recommendation', 'new note', 'same quarter', 'red zone', 'negative trend', 'oversold conditions', 'deeper dive', 'fundamental analysis', 'Operating Margin', 'Gross Margin', 'Net Margin', 'Invested Capital', 'capital structure', 'liquidity data', 'insider ownership', 'approximate value', 'MARSHALL WACE', 'Total Assets', 'Frontline shares', 'outstanding shares', 'consideration shares', '2.88M shares', 'valuable assets', 'RSI result', 'current RSI', 'three-weeks RSI', 'FRO shares', 'RSI rate', '3720420 shares', '5,955,705 shares', '4,457,223 shares', 'NYSE', 'company', 'May', 'world', 'markets', 'OSE', 'EURN', 'Euronext', 'shareholders', '58.97% gains', 'Jefferies', 'estimate', 'opinion', 'April', 'raise', 'The', 'ATR', 'Cash', 'rise', 'Overbought', 'investing', 'hands', 'LLP', '0.', '21.']",2022-06-04,2022-06-05,dbtnews.com
6028,EuroNext,Twitter API,Twitter,@European_DGI By any chance  have you ever looked at #Ageas $AGS on Euronext Brussels? If so  any thought? I'm cons‚Ä¶ https://t.co/lRRo4JlGwz,nan,@European_DGI By any chance  have you ever looked at #Ageas $AGS on Euronext Brussels? If so  any thought? I'm cons‚Ä¶ https://t.co/lRRo4JlGwz,neutral,0.03,0.92,0.05,neutral,0.03,0.92,0.05,True,English,"['Euronext Brussels', 'chance', 'thought', 'lRRo4JlGwz', 'Euronext Brussels', 'chance', 'thought', 'lRRo4JlGwz']",2022-06-05,2022-06-05,Unknown
6029,EuroNext,Twitter API,Twitter,We‚Äôve made it into the top 25 companies on Euronext Amsterdam‚Äôs new AEX¬Æ ESG Index. Head over to the Q&amp;A with our H‚Ä¶ https://t.co/PXLokNmnnx,nan,We‚Äôve made it into the top 25 companies on Euronext Amsterdam‚Äôs new AEX¬Æ ESG Index. Head over to the Q&amp;A with our H‚Ä¶ https://t.co/PXLokNmnnx,neutral,0.04,0.95,0.02,neutral,0.04,0.95,0.02,True,English,"['new AEX¬Æ ESG Index', 'Q&amp;A', 'top 25 companies', 'Euronext Amsterdam', 'PXLokNmnnx', 'new AEX¬Æ ESG Index', 'Q&amp;A', 'top 25 companies', 'Euronext Amsterdam', 'PXLokNmnnx']",2022-06-05,2022-06-05,Unknown
